

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

Association between nut intake and NAFLD risk: a case-control study in a sample of Chinese Han adults

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-028961
Article Type:	Research
Date Submitted by the Author:	07-Jan-2019
Complete List of Authors:	Chen, Bing bing; Fujian Medical University, Han, Ying; The First Affiliated Hospital of Fujian Medical University Pan, Xinting; Department of Epidemiology and Health Statistics, Fujian Provincial Key Laboratory of Environment Factors and Cancer, School of Public Health, Fujian Medical University Yan, Jianhui; Department of Epidemiology and Health Statistics, Fujian Provincial Key Laboratory of Environment Factors and Cancer, School of Public Health, Fujian Medical University Liu, Wenjuan; Department of Epidemiology and Health Statistics, Fujian Provincial Key Laboratory of Environment Factors and Cancer, School of Public Health, Fujian Medical University li, yangfan; Department of Epidemiology and Health Statistics, Fujian Provincial Key Laboratory of Environment Factors and Cancer, School of Public Health, Fujian Medical University, Fujian, China, ; lin, xu; Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fujian, China xu, shanghua; Department of Cardiology, Affiliated Nanping First Hospital, Fujian Medical University, Nanping, China Peng, Xian-E; Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fujian,
Keywords:	EPIDEMIOLOGY, NUTRITION & DIETETICS, Lipid disorders < DIABETES & ENDOCRINOLOGY

SCHOLARONE™
Manuscripts

1
2
3 **Association between nut intake and NAFLD risk: a case-control study in a**
4 **sample of Chinese Han adults**
5
6

7
8 Bingbing Chen^{1#}, Ying Han^{2#}, Xinting Pan¹, Jianhui Yan, Wenjuan Liu¹, Yangfan Li¹, Xu Lin³,
9 Shanghua Xu⁴, Xian-e Peng^{1,3*}

10
11 ¹ Department of Epidemiology and Health Statistics, Fujian Provincial Key
12
13 Laboratory of Environment Factors and Cancer, School of Public Health, Fujian
14
15 Medical University, Fujian, China;

16
17
18 ² The First Affiliated Hospital of Fujian Medical University

19
20 ³ Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian
21
22 Medical University, Fujian, China;

23
24 ⁴ Department of Cardiology, Affiliated Nanping First Hospital, Fujian Medical
25
26 University, Nanping, China

27
28
29 # Both authors contributed equally to this work.

30
31 * Corresponding author. Xian-E Peng, Department of Epidemiology and Health
32
33 Statistics, Fujian Provincial Key Laboratory of Environment Factors and Cancer,
34
35 School of Public Health, Fujian Medical University, Fujian, China, 3501018
36
37 Phone: +86-0591 22862648; E-mail: fमुखe@163.com
38
39

40
41 **Running title:** Nut intake and non-alcoholic fatty liver disease
42
43
44
45

46 **Word count:** 2622
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Background/Objectives: Nut consumption has been associated with a lower risk of type 2 diabetes, metabolic syndrome, and insulin resistance. However, its effect on the risk of non-alcoholic fatty liver disease (NAFLD) is unknown. Therefore, we investigated the relationship between nut consumption and NAFLD risk.

Subjects/Methods: A case-control study was conducted among 534 patients diagnosed with NAFLD and 534 controls matched by sex and age (± 5) from the Affiliated Nanping First Hospital of Fujian Medical University in China. Information on dietary intake was collected using a semi-quantitative food frequency questionnaires and nut consumption was calculated. Nut consumption was categorized using quartiles based on the distribution of daily nut intake of the controls. Binary logistic regression models were used to estimate odds ratio (ORs) and the 95% confidence intervals (CIs) for the association between nut consumption and NAFLD risk.

Results: After adjusting for potential confounding variables, nut consumption was not associated with NAFLD risk in the overall sample. When the fully adjusted model was stratified by sex, a significant inverse association was found between high nut consumption and NAFLD only among the men in the highest quartile (OR = 0.45; 95% CI: 0.27–0.76; $P_{\text{trend}} = 0.01$). The inverse association of nut consumption with NAFLD risk in men remained significant after controlling for other known or suspected risk factors for NAFLD.

Conclusions: Diets with a higher intake of nuts may be associated with a decreased risk of NAFLD, particularly in men.

Keywords: NAFLD ; Nut consumption ; case-control study

Introduction

Non-alcoholic fatty liver disease (NAFLD) is defined as macrovesicular steatosis in $\geq 5\%$ of hepatocytes, in the absence of a secondary cause, such as alcohol or drug use. NAFLD has become a leading cause of chronic liver disease, with a 25% prevalence worldwide¹. Furthermore, a fatty liver is more prevalent in men compared with women². The prevalence of NAFLD among the adults in China's general population is approximately 15% (6.3–27.0%), depending on the population studied³. Many studies suggest that diet and lifestyle may significantly influence the risk of NAFLD^{4, 5}. These studies indicate that type 2 diabetes (T2D)⁶, metabolic syndrome (MetS), obesity⁷, physical activity, and a high-fat diet⁴ are associated with an increased risk for the development of NAFLD.

Nuts are nutrient-dense foods with complex matrices rich in unsaturated fatty and other bioactive compounds (e.g., high-quality vegetable protein, fiber, minerals, tocopherols, phytosterols, and phenolic compounds)⁸. The global intake of nuts has increased by 59% over the past decade⁹. China's per capita intake of nuts was 2.2 g/day in 1982, and increased to 3.8g/day in 2012¹⁰. Although they are high in fat and energy dense, a high intake of nuts has been associated with several health benefits, including reduced risk of cardiovascular disease¹¹, T2D¹², MetS¹³, and insulin resistance^{14, 15}. Moreover, nuts have antioxidative effects by decreasing lipid peroxidation and protecting against oxidative DNA damage¹⁶. Beneficial health effects have been attributed to the macronutrient and micronutrient profiles of nuts¹⁷.

NAFLD is regarded as the "hepatic manifestation of MetS." Few studies have assessed the effects of nut intake on NAFLD, despite previous findings of an inverse correlation between high nut consumption and the risk of T2D and cardiovascular disease. In this study, we analyzed the association between nut intake and NAFLD

1
2
3 risk and the interactions between nut intake and other established NAFLD risk factors
4
5 in a large case-control study with a sample of Han adults in China.
6
7

8 **Patient and Public Involvement**

9
10 This study is a case-control design focused on a Chinese Han population between
11
12 18 and 70 years old. Subjects were recruited from a health examination center of
13
14 Nanping First Affiliated Hospital of Fujian Medical University from October 2015 to
15
16 September 2017. All subjects underwent abdominal ultrasound and blood biochemical
17
18 tests. Once cases and controls have been linked to the NAFLD, a letter of invitation
19
20 and information about the study will be sent to each potential case and control to
21
22 obtain consent. Eligible subjects will be interviewed face-to-face by investigators to
23
24 collect data. The study was approved by the local ethics committees of Fujian
25
26 Medical University (ethics number 2014096). In addition, all methods were performed
27
28 in accordance with the relevant guidelines and regulations.
29
30
31

32 **Subjects and Methods**

33 **Participants and study design**

34
35 We conducted the case-control study in a health examination center at the
36
37 Affiliated Nanping First Hospital of Fujian Medical University from April 2015 to
38
39 August 2017. Patients newly diagnosed with NAFLD using ultrasonography in
40
41 accordance with the “Guidelines for the diagnosis and treatment of nonalcoholic fatty
42
43 liver disease in China” were included in the study. All participants were of Chinese
44
45 Han ethnicity. The exclusion criteria were as follows: (a) daily alcohol intake of >40 g
46
47 (men) and >20 g (women), (b) a history of other liver diseases including drug-induced
48
49 liver disease, viral hepatitis, autoimmune hepatitis, total parenteral nutrition, and
50
51 hepatolenticular degeneration, (c) taking hypolipidemic or weight reduction drugs, (d)
52
53 age <18 or >70 years, (e) non-resident of Nanping, or (f) not of Han ethnicity. Adults
54
55
56
57
58
59
60

1
2
3 who reported extremely abnormal levels of energy intake (2 511.60 kJ [600 kcal] or
4
5 17 581.20 kJ [4 200kcal] per day for men; 2 093 kJ [500 kcal] or 14,651.00 kJ [3500
6
7 kcal] per day for women), and those who did not answer 25 or more food-related
8
9 items or questions about nut intake on the questionnaire, were excluded from the
10
11 study.
12
13

14
15 The controls were randomly selected from the same center during the study period.
16
17 Their eligibility criteria were identical to those of the cases, except for the
18
19 requirement of a diagnosis of liver steatosis; they were frequency-matched with cases
20
21 by age (within 5-yr intervals), gender, ethnicity, and region of origin. The study was
22
23 approved by the local ethics committee of Fujian Medical University. All procedures
24
25 were performed in accordance with relevant guidelines and regulations, and all
26
27 participants provided written informed consent.
28
29

30 31 **Dietary Assessment**

32
33 Trained interviewers performed a comprehensive medical history on each
34
35 participant that included eliciting information about their demographic and
36
37 socio-economic characteristics, and lifestyle habits (e.g., smoking, drinking (alcohol),
38
39 tea drinking, and physical activity). The data were obtained from participants using
40
41 structured questionnaires during face-to-face interviews. Information about
42
43 participants' typical food consumption was collected using a semi-quantitative food
44
45 frequency questionnaire, which was developed and validated in a sample from
46
47 southern China ¹⁸. Participants were asked to estimate the average frequency of
48
49 consumption of selected foods using the following response options: rarely,
50
51 <once/month, 1–3 times/month, 1–2 times/week, 3–4 times/week, 5–6 times/week,
52
53 once/day, twice/day, and >twice/day. Nut intake was defined as the consumption of
54
55 “peanuts, walnuts, seeds, or other nuts.” Data from a semi-quantitative food frequency
56
57
58
59
60

1
2
3 questionnaire were used to calculate daily nut and energy intake. Nut consumption
4 was converted to grams/day by multiplying the food-intake frequency by fixed
5 portion sizes. Nutrient intake, such as mono-unsaturated fatty acids (MUFAs) and
6 poly-unsaturated fatty acids (PUFAs) were calculated by multiplying the intake
7 frequency of each food by the nutrient content of the specified portion, and summing
8 the products of all the food items.
9

17 **Statistical analysis**

19 Participants' characteristics were analyzed using Pearson's Chi-square test for
20 categorical variables, and Wilcoxon's rank-sum test and ANOVA for continuous
21 variables. Nut consumption was categorized by quartiles based on the distribution of
22 daily nut intake by the controls (Q1-Q4). Binary logistic regression models were used
23 to estimate the odds ratios (ORs) and their 95% confidence intervals (CIs) for the
24 associations between nut consumption and NAFLD risk. To account for the energy
25 content of the nut, our initial model adjusted for total energy intake by using the
26 residuals method. The final model adjusted for potential confounders, including age,
27 income, smoking status, educational level, and tea-drinking status, occupational status,
28 marital status, body mass index (BMI), physical activity (The intensity of physical
29 activity was defined in terms of Metabolic Equivalent of Energy (MET). According to
30 a standard reference, each kind of activity was assigned a specific MET value: light
31 physical activities were defined as <3 METs, moderate activities defined as 3~6 METs
32 and severe activities defined as >6 METs). The total dose of physical activity equals
33 the sum of the doses for each specific activity., and history of diabetes, hypertension,
34 and hyperlipidemia. The final model also adjusted for MUFA and PUFA intake to
35 control for their effects. The selection of covariates for the final model was based on
36 clinical significance, results of previous studies, and strength of the correlation with
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 exposure. We tested for linear trends across categories of nut intake by assigning each
4 participant the median value for each category and modeling this value as a
5 continuous variable.
6
7
8
9

10 We evaluated the influence of nut consumption across strata of other potential
11 predictors and confounders, comparing participants in the highest nut-consumption
12 category to the lowest nut-consumption category(reference). We also analyzed the
13 interactions of nut consumption with age, sex, BMI, smoking status, educational level,
14 tea-drinking status, and other risk factors. We used the medians of the continuous
15 variables to categorize them and evaluate the interactions. The criteria for statistical
16 significance of the likelihood-ratio test of interaction effects was $P < 0.05$. Statistical
17 analyses were performed using SPSS version 22 (IBM, Armonk, NY, US). All
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

P-values were 2-tailed, and *P* < 0.05 was considered statistically significant.

Table 1 General characteristics of cases and controls stratified by sex, *n*(%)

Variables	Men (<i>n</i> =728)			Women(<i>n</i> =340)		
	Cases	Controls(<i>n</i> =364)	<i>P</i> -value ^a	Cases (<i>n</i> =170)	Controls(<i>n</i> =170)	<i>P</i> -value ^a
Age			0.66			0.99
<40	118(32.42)	116(31.87)		25(14.71)	22(12.94)	
40~60	217(59.61)	212(58.24)		123(72.35)	122(71.76)	
≥60	29(7.97)	36(9.89)		22(12.94)	26(15.30)	
Educational level			0.04			0.75
primary school and less than	10(2.75)	23(6.32)		30(17.65)	26(15.29)	
junior middle and high school	147(40.38)	128(35.16)		76(44.70)	74(43.53)	
junior college or above	207(56.87)	213(58.52)		64(37.65)	70(41.18)	
Occupational status			0.39			0.43
mental labour	108(29.67)	104(28.57)		50(29.41)	48(28.24)	
physical labor	86(23.63)	102(28.02)		25(14.71)	34(20.00)	
other	170(46.70)	158(43.41)		95(55.88)	88(51.76)	
Income(yuan/month)			0.35			0.85
<2000	17(4.67)	17(4.67)		15(8.82)	18(10.59)	
2000~3000	87(23.90)	104(28.57)		70(41.18)	70(41.18)	
≥3000	260(71.43)	243(66.76)		85(50.00)	82(48.23)	
Marital status			0.24			0.52
single	45(12.36)	56(15.38)		4(2.35)	6(3.53)	
married or other	319(87.64)	308(84.62)		166(97.65)	164(96.47)	
Smoking status			0.30			0.16
never smoker	199(54.67)	213(58.52)		168(98.82)	170(100)	
smoker	165(45.33)	151(41.48)		2(1.18)	0(0.00)	
Tea-drinking status			0.30			0.01
yes	258(70.88)	245(63.31)		77(45.29)	55(32.35)	
no	106(29.12)	119(32.69)		93(54.71)	115(67.55)	
Physical activity			0.02			0.88
light	175(48.08)	137(37.64)		19(11.18)	19(11.18)	
moderate	100(27.47)	121(33.24)		47(27.64)	43(25.29)	
severe	89(24.45)	106(29.12)		104(61.18)	108(63.53)	
BMI(kg/m ²)			0.00			0.00
<18.5	2(0.55)	11(3.02)		1(0.59)	9(5.29)	
18.5~24.0	107(29.40)	257(70.61)		72(42.35)	125(73.53)	
≥24.0	255(70.05)	96(26.37)		97(57.06)	36(21.18)	
History of diabetes			0.67			0.18
yes	12(3.30)	10(2.75)		10(5.88)	5(2.94)	
no	352(96.70)	354(97.25)		160(94.12)	165(94.06)	
History of hypertension			0.85			0.63
yes	15(4.12)	16(4.40)		8(4.71)	10(5.88)	
no	349(95.88)	348(95.60)		162(95.29)	160(94.12)	
History of hyperlipidemia			0.01			0.00
yes	108(29.67)	77(21.15)		51(30.00)	21(12.35)	
no	256(70.33)	287(78.85)		119(70.00)	149(87.65)	
MUFA intake,g/d ^b	34.10(28.49, 31.39)	26.55(26.55, 36.79)	0.00	29.99(26.37, 36.37)	28.05(22.40, 31.39)	0.00
PUFA intake,g/d ^b	26.25(24.04, 23.90)	22.01(26.02)	0.00	24.52(22.11, 27.12)	21.21(18.83, 24.53)	0.00
Energy intake,kJ/d ^c	10395.64±24989.07	97±2348.76	0.01	7509.73±1650.71	7323.78±1852.97	0.04

^a*P*-values were calculated by using the Chi-square test for categorical variables and Wilcoxon rank sum test and ANOVA test for continues variables.

^bMedians (IQRs).

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

^cMean(s.d).

Results

Baseline Characteristics

Table 1 presents health-related and demographic characteristics of the NAFLD cases and matched controls. Compared with the controls, the NAFLD cases tended to have a higher BMI, higher total intake of energy, higher MUFA and PUFA consumption, and a higher number of participants with a history of hyperlipidemia among both men and women. Patients with NAFLD had a lower educational level and the men engaged in less physical activity than the controls. No statistically significant associations were found for age, occupational status, income, marital status, smoking status, history of diabetes, or hypertension between the cases and the controls.

The associations of dietary nut intake with NAFLD

The participants' nut consumption is summarized in Table 2. Among the women, those in the NAFLD group consumed a significantly higher amount of nuts (6.80 g/d vs. 2.50 g/d; $P = 0.02$) than those in the control group. No statistically significant differences were found between the cases and controls in the the sample or among the male participants. In order to adjust for potential confounding factors, quartile distributions of dietary nut consumption among the controls were used to categorize the nut intake of all the participants; the results are shown in Table 3. After adjusting for potential confounders, nut consumption was not associated with NAFLD risk among the participants in the sample. When the fully adjusted model was stratified by sex, a significant inverse association was found between nut consumption and NAFLD, but only among the men in the highest quartile (OR = 0.45; 95% CI: 0.27–0.76; $P_{\text{trend}} = 0.01$).

Table 2 Comparison of nut daily intake between the case and the control

Nut intake (g/d)	Case		Control		<i>P</i> -value ^a	<i>P</i> -value ^b
	Median	Quartile	Median	Quartile		
Total population	3.15	1.46-8.80	2.86	1.22-8.98	0.35	0.18
Men	2.68	1.15-8.43	2.86	1.22-8.98	0.36	0.94
Women	6.80	1.75-8.86	2.50	1.07-7.84	0.01	0.02

^a*P*-values:calculated by using Wilcoxon rank sum test;before adjusting for energy.

^b*P*-values :calculated by using Wilcoxon rank sum test; after adjusting for energy by using the residuals methods.

Table 3 Odds ratios (OR) and 95% confidence intervals (CI) for NAFLD in relation to nut intake

Nut intake	Case <i>n</i>	Control <i>n</i>	Crude OR(95%CI)	Model 1 ^a OR(95%CI)	Model 2 ^a OR(95%CI)
Total population ^b	534	534			
Q1	125	133	1	1	1
Q2	112	134	1.30(0.93-1.81)	0.89(0.63-1.26)	0.98(0.65-1.47)
Q3	159	134	1.77(1.29-2.44)	1.26(0.90-1.77)	1.16(0.78-1.72)
Q4	138	133	1.17(0.81-1.68)	1.10(0.78-1.55)	0.85(0.57-1.27)
<i>P</i> for trend*			0.46	0.45	0.07
Men	364	364			
Q1	106	102	1	1	1
Q2	91	79	1.31(0.88-1.94)	0.90(0.60-1.35)	0.92(0.56-1.49)
Q3	74	123	1.81(1.24-2.65)	1.73(1.16-2.57)	1.36(0.85-2.18)
Q4	93	60	1.04(0.66-1.63)	0.67(0.44-1.02)	0.45(0.27-0.76)
<i>P</i> for trend*			0.81	0.04	0.01
Women	170	170			
Q1	23	27	1	1	1
Q2	33	43	1.28(0.69-2.37)	0.90(0.44-1.85)	0.86(0.37-2.02)
Q3	36	60	1.71(0.95-3.08)	0.70(0.35-1.41)	0.56(0.25-1.28)
Q4	78	40	1.41(0.76-2.64)	2.29(1.17-4.49)	1.34(0.59-3.04)
<i>P</i> for trend*			0.36	0.00	0.12

^aModel 1:Adjusted for total energy intake.

^aModel 2:Adjusted further for age,income,smoking status,educational level, teaing status, occupationanl status,marital status,body mass index,physical activity,the history of diabetes,hypertension and hyperlipidemia,MUFA and PUFA intake.

^b:further adiuusted for sex.

**P* for trend: Trend across intake levels with the categorical median.

Stratified Analyses

In the stratified analysis, the inverse association between total-nut consumption and NAFLD risk was consistent across age, sex, BMI, educational level, income, physical activity, smoking, tea drinking, and history of diabetes, hypertension, and hyperlipidemia. In addition to the association between nut consumption and NAFLD in men, we also found the highest nut-consumption category was associated with a lower risk of developing NAFLD than the reference (OR = 0.53; 95% CI: 0.31–0.93) among the participants who engaged in light and moderate physical activity. No significant interactions of total nut consumption and the potentially modifying effects of NAFLD risk factors were identified (Figure 1).

Discussion

In this case-control study, we found a significant inverse relationship between high nut consumption and NAFLD risk among the males, but found either no or unclear associations among the females and the overall sample. Moreover, the associations seemed to be independent of other predictors, including diet and lifestyle factors. The effect of nut consumption remained among men after controlling for other known or suspected risk factors for developing NAFLD. Furthermore, no significant interactions between nut consumption and the potential modifying effects of NAFLD risk factors were identified. To the best of our knowledge, this was the first study to assess the association between nut consumption and the risk of NAFLD in a Chinese sample.

Our results are consistent with a previous study conducted in Korea, which found that a low intake of nuts and seeds (OR = 3.66; $P_{\text{trend}} = 0.007$) was associated with a significantly higher risk of developing NAFLD among male participants, but not among females¹⁹. Although another case-control study found an association between

1
2
3 a high intake of nuts with a lower likelihood of NAFLD, after adjusting for the
4 confounders age, sex, waist circumference, and the values of the homeostasis model
5 assessment of insulin resistance (OR = 0.61; 95% CI: 0.38–0.98), the association
6 disappeared after further adjustment for adiponectin and TNF- α (OR = 0.72; 95% CI:
7 0.41–1.25)²⁰. However, the study did not examine nut intake separately; therefore,
8 the results cannot be directly compared with those of our study. Although the results
9 of our study suggest nuts may play a protective role in the development of NAFLD in
10 males, a significant association between nut intake and the risk of NAFLD was not
11 found in females. NAFLD has been regarded as the “hepatic manifestation of MetS”;
12 therefore, our findings are indirectly supported by several studies showing an inverse
13 correlation between high nut intake and the risk of T2D and cardiovascular disease,
14 which share common metabolic parameters with NAFLD²¹⁻²³. Nevertheless, the
15 relationship between nut intake and NAFLD warrants further exploration, and
16 additional studies are needed to examine gender differences in the association
17 between nut consumption and NAFLD, and its’ possible mechanisms should be
18 explored.

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40 Several biological pathways have been proposed to explain the association
41 between nut intake and NAFLD risk. Ellagic acid, a natural antioxidant polyphenol
42 found in nuts, can suppress oxidative stress and inflammation²⁴ and improve hepatic
43 insulin sensitivity and lipid metabolism²⁵. Vitamin E and selenium in almonds and
44 walnuts, as well as folic acid and resveratrol in pine nuts, have been reported to have
45 beneficial effects on NAFLD. Numerous trials testing the therapeutic value of vitamin
46 E in NAFLD prevention found that Vitamin E significantly improved liver function
47 and histologic changes by significantly reducing aspartate aminotransferase, alanine
48 aminotransferase, steatosis, and inflammation in patients with NAFLD/non-alcoholic
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 steatohepatitis (NASH) ²⁶. Selenium is an antioxidant agent, and selenium deficiency
4 is associated with insulin resistance in patients with chronic liver disease ²⁷. Folate
5 plays an essential role in lipid metabolism and folic acid supplementation can
6 attenuate steatosis and improve oxidative stress in rodent models of NAFLD. Folate
7 can also blunt the increase of inflammatory cytokines secreted by immune cells ²⁸.
8 Resveratrol has antioxidant, anti-apoptotic, and anti-inflammatory properties in
9 NAFLD patients ²⁹. Nuts, which are known to be rich in unsaturated fatty acids, are
10 especially rich in n-3 PUFAs, a source of alpha-linolenic acid, which lowers LDL
11 cholesterol ³⁰, and has been found to have beneficial effects on NAFLD ³¹. Each type
12 of nut has many nutrients and phytochemicals that may be beneficial to health, and it
13 is likely that unknown salubrious effects of nuts may be related to NAFLD prevention.
14 Moreover, many studies have shown a beneficial association between high nut intake
15 and decreased risk of obesity ³², T2D ³³, and MetS ³⁴, which are risk factors for
16 NAFLD.

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35 Our study has both strengths and limitations. The first strength is the large sample
36 size, which may have reduced type II errors. Second, the collection of data using
37 face-to-face interviews and a semi-quantitative food frequency questionnaire, which
38 elicited extensive information on anthropometrics and lifestyle factors, allowed us to
39 adjust for confounding factors. Finally, the study had sufficient power to investigate
40 interactions between nut intake and other risk factors, for which a biologically
41 plausible mechanism may exist. Nonetheless, several limitations should be considered
42 when interpreting the study's findings. First, although we accounted for a wide range
43 of socioeconomic characteristics and lifestyle factors, we cannot exclude the effects of
44 unknown or poorly measured confounding variables or residual confounding
45 attributable to other dietary/lifestyle factors, which might have influenced the
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 observed associations. However, the associations persisted even after controlling for
4 known and suspected predictors of NAFLD. Second, the intake of nuts was assessed
5 by asking about using one question; therefore, we could not investigate the effects of
6 different types of nuts, such as peanuts and walnuts, which contain different amounts
7 of energy, fat content, and other nutrients³⁵. Third, we did not consider manufacturing
8 methods (e.g., raw, roasted, or boiled) or extra ingredients (e.g., sugar, salt, seasoning).
9 Different preparation methods before and after roasting, the amount of time roasted,
10 and the temperature used can affect the nutrient composition and ingredients in the
11 nuts^{36, 37}. Fourth, because we used a case-control study design, recall bias is an
12 inherent limitation. People who are health-conscious may over-report or under-report
13 some food items. However, the protective effect of nuts on NAFLD was not generally
14 known at the time of the survey, and thus, should be unrelated to recall bias. Finally,
15 due to the small number of participants in the highest nut-intake category, we cannot
16 rule out the possibility that some of our results are due to chance. However, the
17 associations were consistent in the analyses stratified by some of the other factors,
18 which reduces the likelihood of chance findings. In these stratified analyses, the
19 statistical power needed to detect differences was limited by the sample size, and such
20 analyses should be considered exploratory.

21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45 Our study had a retrospective design, which is lower on the evidence hierarchy than
46 prospective studies. Nevertheless, case-control studies can provide evidence
47 supporting the general relationship between diet and NAFLD, as there currently are
48 no available prospective studies.

49
50
51
52
53
54 In conclusion, this case-control study indicated that high nut intake was associated
55 with a significantly reduced risk of NAFLD among Han men in China. However, no
56 relationship was found between total nut intake and NAFLD risk among the Han
57
58
59
60

1
2
3 women. Our data contribute to the growing evidence showing that a relatively simple
4 prevention strategy of incorporating a modest amount of nuts in the diet may
5 contribute to maintaining good health at both the individual and population levels.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Acknowledgements

We thank all study participants for their cooperation. We also thank our staff for recruiting participants and for their technical assistance.

Contributors

BBC and YH are joint first authors. XEP obtained funding. XEP, XL and SHX designed the study. XTP, JHY, YFL and WJL collected the data. BBC and YH were involved in data cleaning and verification. BBC and XTP analyzed the data. BBC and YH drafted the manuscript. XEP, YFL and JHY contributed to the interpretation of the results and critical revision of the manuscript for important intellectual content and approved the final version of the manuscript. All authors have read and approved the final manuscript.

Data sharing

No additional data are available.

Conflict of Interest

The authors declare that they have no conflict of interest.

Funding

This work was supported by the National Natural Science Foundation of China [grant number 81473047], the Training Program Foundation for Middle-aged and Young Talents from the Sanitation System of Fujian Province [grant number 2014-ZQN-ZD-23], and the Joint Innovation Project of Science and Technology of Fujian Province [grant number 2017Y9104].

References

- 1 Maurice J, Manousou P. Non-alcoholic fatty liver disease. *Clin Med (Lond)* 2018; **18(3)**: 245-250.
- 2 Rietman A, Sluik D, Feskens E, Kok F, Mensink M. Associations between dietary factors and markers of NAFLD in a general Dutch adult population. *Eur J Clin Nutr* 2018; **72(1)**: 117-123.
- 3 Fan J. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. *J Gastroenterol. Hepatol.* 2013; **28 Suppl 1**: 11-17.
- 4 Katsagoni C, Georgoulis M, Papatheodoridis G, Panagiotakos D, Kontogianni M. Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. *Metab. Clin. Exp.* 2017; **68**: 119-132.
- 5 Zelber-Sagi S, Salomone F, Mlynarsky L. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanisms. *Liver Int.* 2017; **37(7)**: 936-949.
- 6 Kosmidou M, Milionis H. Diabetes mellitus and non-alcoholic fatty liver disease: the thread of Ariadne. *Minerva Endocrinol.* 2017; **42(2)**: 109-121.
- 7 Petrović G, Bjelaković G, Benedeto-Stojanov D, Nagorni A, Brzački V, Marković-Živković B. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound. *Vojnosanit Pregl* 2016; **73(10)**: 910-920.
- 8 Ros E. Health benefits of nut consumption. *Nutrients* 2010; **2(7)**: 652-682.

- 1
2
3
4 9 Lee J, Shin A, Oh JH, Kim J. The relationship between nut intake and risk of
5
6 colorectal cancer: a case control study. *Nutr J* 2018; **17**(1): 37.
7
8
9 10 Lahong J, Dongmei Y, Xiaoli X. Status and variation trend of nut intake among
10
11 Chinese residents,2010-2012. *Chin J Public Health* 2017; **33**(6): 916-918.
12
13
14 11 Larsson S, Drca N, Björck M, Bäck M, Wolk A. Nut consumption and incidence
15
16 of seven cardiovascular diseases. *Heart* 2018.
17
18
19 12 Asghari G, Ghorbani Z, Mirmiran P, Azizi F. Nut consumption is associated with
20
21 lower incidence of type 2 diabetes: The Tehran Lipid and Glucose Study. *Diabetes*
22
23 *Metab.* 2017; **43**(1): 18-24.
24
25
26
27 13 O'Neil C, Fulgoni V, Nicklas T. Tree Nut consumption is associated with better
28
29 adiposity measures and cardiovascular and metabolic syndrome health risk factors in
30
31 U.S. Adults: NHANES 2005-2010. *Nutr J* 2015; **14**: 64.
32
33
34
35 14 Casas-Agustench P, López-Uriarte P, Bulló M, Ros E, Cabré-Vila J, Salas-Salvadó
36
37 J. Effects of one serving of mixed nuts on serum lipids, insulin resistance and
38
39 inflammatory markers in patients with the metabolic syndrome. *Nutr Metab*
40
41 *Cardiovasc Dis* 2011; **21**(2): 126-135.
42
43
44
45 15 Hernández-Alonso P, Salas-Salvadó J, Baldrich-Mora M, Juanola-Falgarona M,
46
47 Bulló M. Beneficial effect of pistachio consumption on glucose metabolism, insulin
48
49 resistance, inflammation, and related metabolic risk markers: a randomized clinical
50
51 trial. *Diabetes Care* 2014; **37**(11): 3098-3105.
52
53
54
55
56 16 Grosso G, Yang J, Marventano S, Micek A, Galvano F, Kales S. Nut consumption
57
58 on all-cause, cardiovascular, and cancer mortality risk: a systematic review and
59
60

1
2
3
4 meta-analysis of epidemiologic studies. *Am. J. Clin. Nutr.* 2015; **101**(4): 783-793.

5
6
7 17 Dreher M, Maher C, Kearney P. The traditional and emerging role of nuts in
8
9 healthful diets. *Nutr. Rev.* 1996; **54**(8): 241-245.

10
11
12 18 Ke L, Toshiro T, Fengyan S, Ping Y, Xiaoling D, Kazuo T. Relative validity of a
13
14 semi-quantitative food frequency questionnaire versus 3 day weighed diet records in
15
16 middle-aged inhabitants in Chaoshan area, China. *Asian Pac J Cancer Prev* 2005;
17
18 **6**(3): 376-381. e-pub ahead of print 2005/10/21.

19
20
21
22 19 Han JM, Jo AN, Lee SM, Bae HS, Jun DW, Cho YK *et al.* Associations between
23
24 intakes of individual nutrients or whole food groups and non-alcoholic fatty liver
25
26 disease among Korean adults. *Journal of Gastroenterology and Hepatology* 2014;
27
28 **29**(6): 1265-1272.

29
30
31
32 20 Katsagoni C, Georgoulis M, Papatheodoridis G, Fragopoulou E, Ioannidou P,
33
34 Papageorgiou M *et al.* Associations Between Lifestyle Characteristics and the
35
36 Presence of Nonalcoholic Fatty Liver Disease: A Case-Control Study. *Metab Syndr*
37
38 *Relat Disord* 2017; **15**(2): 72-79.

39
40
41
42 21 Edens M, Kuipers F, Stolk R. Non-alcoholic fatty liver disease is associated with
43
44 cardiovascular disease risk markers. *Obes Rev* 2009; **10**(4): 412-419.

45
46
47
48 22 Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S *et al.*

49
50 Fatty liver is associated with an increased risk of diabetes and cardiovascular disease -
51
52 Evidence from three different disease models: NAFLD, HCV and HIV. *World J.*
53
54 *Gastroenterol.* 2016; **22**(44): 9674-9693.

55
56
57
58 23 Gastaldelli A. Insulin resistance and reduced metabolic flexibility: cause or
59
60

1
2
3
4 consequence of NAFLD? *Clin. Sci.* 2017; **131**(22): 2701-2704.

5
6 24 Panchal SK, Ward L, Brown L. Ellagic acid attenuates high-carbohydrate, high-fat
7
8 diet-induced metabolic syndrome in rats. *Eur J Nutr* 2013; **52**(2): 559-568.

9
10
11 25 Polce S, Burke C, França L, Kramer B, de Andrade Paes A, Carrillo-Sepulveda M.
12
13 Ellagic Acid Alleviates Hepatic Oxidative Stress and Insulin Resistance in Diabetic
14
15 Female Rats. *Nutrients* 2018; **10**(5): 1-15.

16
17 26 Sato K, Gosho M, Yamamoto T, Kobayashi Y, Ishii N, Ohashi T *et al.* Vitamin E
18
19 has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of
20
21 randomized controlled trials. *Nutrition* 2015; **31**(7-8): 923-930.

22
23 27 Himoto T, Yoneyama H, Kurokohchi K, Inukai M, Masugata H, Goda F *et al.*
24
25 Selenium deficiency is associated with insulin resistance in patients with hepatitis C
26
27 virus-related chronic liver disease. *Nutr Res* 2011; **31**(11): 829-835.

28
29 28 Sid V, Siow Y, O K. Role of folate in nonalcoholic fatty liver disease. *Can. J.*
30
31 *Physiol. Pharmacol.* 2017; **95**(10): 1141-1148.

32
33 29 Hajighasem A, Farzanegi P, Mazaheri Z. Effects of combined therapy with
34
35 resveratrol, continuous and interval exercises on apoptosis, oxidative stress, and
36
37 inflammatory biomarkers in the liver of old rats with non-alcoholic fatty liver disease.
38
39 *Arch. Physiol. Biochem.* 2018: 1-8.

40
41 30 Jeznach-Steinhagen A, Ostrowska J, Czerwonogrodzka-Senczyna A, Boniecka I,
42
43 Gronostajska W. [Dietary recommendation for non-alcoholic fatty liver disease].
44
45 *Pol. Merkur. Lekarski* 2017; **43**(258): 281-286.

46
47 31 Musa-Veloso K, Venditti C, Lee H, Darch M, Floyd S, West S *et al.* Systematic
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 review and meta-analysis of controlled intervention studies on the effectiveness of
5
6 long-chain omega-3 fatty acids in patients with nonalcoholic fatty liver disease. *Nutr.*
7
8
9 *Rev.* 2018; **0(0)**: 1-22.

10
11 32 Mohammadifard N, Yazdekhashti N, Stangl G, Sarrafzadegan N. Inverse
12
13 association between the frequency of nut consumption and obesity among Iranian
14
15 population: Isfahan Healthy Heart Program. *Eur J Nutr* 2015; **54(6)**: 925-931.

16
17 33 Hernández-Alonso P, Camacho-Barcia L, Bulló M, Salas-Salvadó J. Nuts and
18
19 Dried Fruits: An Update of Their Beneficial Effects on Type 2 Diabetes. *Nutrients*
20
21
22 2017; **9(7)**: 673.

23
24 34 Hosseinpour-Niazi S, Hosseini S, Mirmiran P, Azizi F. Prospective Study of Nut
25
26 Consumption and Incidence of Metabolic Syndrome: Tehran Lipid and Glucose
27
28 Study. *Nutrients* 2017; **9(10)**: 1056.

29
30 35 Wu L, Wang Z, Zhu J, Murad AL, Prokop LJ, Murad MH. Nut consumption and
31
32 risk of cancer and type 2 diabetes: a systematic review and meta-analysis. *Nutr Rev*
33
34 2015; **73(7)**: 409-425.

35
36 36 Schlörmann W, Birringer M, Böhm V, Löber K, Jahreis G, Lorkowski S *et al.*
37
38 Influence of roasting conditions on health-related compounds in different nuts. *Food*
39
40
41 *Chem* 2015; **180**: 77-85.

42
43 37 Hosseini Bai S, Darby I, Nevenimo T, Hannel G, Hannel D, Poienou M *et al.*
44
45 Effects of roasting on kernel peroxide value, free fatty acid, fatty acid composition
46
47 and crude protein content. *PLoS ONE* 2017; **12(9)**: e0184279.

Figure legends

Figure 1. Odds ratios (OR) and 95% CIs for NAFLD across the strata of various factors.

The forest plot represents the ORs of the comparison of the lowest nut-intake category versus the highest nut-intake category, adjusting for age, income, smoking status, educational level, tea-drinking status, occupational status, marital status, BMI, physical activity, history of diabetes, hypertension and hyperlipidemia, total energy intake, and MUFA and PUFA intake. P -values are two-tailed; P_{inter} indicates P for the interaction between strata and nut intake; P_{trend} indicates P for the trend across levels of nut intake.




Figure 1. Odds ratios (OR) and 95% CIs for NAFLD across the strata of various factors. The forest plot represents the ORs of the comparison of the lowest nut-intake category versus the highest nut-intake category, adjusting for age, income, smoking status, educational level, tea-drinking status, occupational status, marital status, BMI, physical activity, history of diabetes, hypertension and hyperlipidemia, total energy intake, and MUFA and PUFA intake. P-values are two-tailed; Pinter indicates P for the interaction between strata and nut intake; Ptrend indicates P for the trend across levels of nut intake.

148x159mm (96 x 96 DPI)

BMJ Open

Association between nut intake and Non-alcoholic fatty liver disease risk: a retrospective case-control study in a sample of Chinese Han adults

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-028961.R1
Article Type:	Research
Date Submitted by the Author:	27-Apr-2019
Complete List of Authors:	Chen, Bing bing; Fujian Medical University, Han, Ying; The First Affiliated Hospital of Fujian Medical University Pan, Xinting; Department of Epidemiology and Health Statistics, Fujian Provincial Key Laboratory of Environment Factors and Cancer, School of Public Health, Fujian Medical University Yan, Jianhui; Department of Epidemiology and Health Statistics, Fujian Provincial Key Laboratory of Environment Factors and Cancer, School of Public Health, Fujian Medical University Liu, Wenjuan; Department of Epidemiology and Health Statistics, Fujian Provincial Key Laboratory of Environment Factors and Cancer, School of Public Health, Fujian Medical University li, yangfan; Department of Epidemiology and Health Statistics, Fujian Provincial Key Laboratory of Environment Factors and Cancer, School of Public Health, Fujian Medical University, Fujian, China, ; lin, xu; Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fujian, China xu, shanghua; Department of Cardiology, Affiliated Nanping First Hospital, Fujian Medical University, Nanping, China Peng, Xian-E; Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fujian,
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Nutrition and metabolism, Public health
Keywords:	EPIDEMIOLOGY, NUTRITION & DIETETICS, Lipid disorders < DIABETES & ENDOCRINOLOGY

SCHOLARONE™
Manuscripts

1
2
3 **Association between nut intake and Non-alcoholic fatty liver disease risk: a**
4 **retrospective case-control study in a sample of Chinese Han adults**
5
6

7 Bingbing Chen^{1#}, Ying Han^{2#}, Xinting Pan¹, Jianhui Yan¹, Wenjuan Liu¹, Yangfan Li¹, Xu Lin³,
8 Shanghua Xu⁴, Xian-e Peng^{1,3*}
9

10 ¹ Department of Epidemiology and Health Statistics, Fujian Provincial Key
11 Laboratory of Environment Factors and Cancer, School of Public Health, Fujian
12 Medical University, Fujian, China;
13
14

15
16
17 ² The First Affiliated Hospital of Fujian Medical University
18

19 ³ Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian
20 Medical University, Fujian, China;
21
22

23
24 ⁴ Department of Cardiology, Affiliated Nanping First Hospital, Fujian Medical
25 University, Nanping, China
26
27

28 [#] Both authors contributed equally to this work.
29

30 ^{*} Corresponding author. Xian-E Peng, Department of Epidemiology and Health
31 Statistics, Fujian Provincial Key Laboratory of Environment Factors and Cancer,
32 School of Public Health, Fujian Medical University, Fujian, China, 3501018
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Phone: +86-0591 22862648; E-mail: fmuxe@163.com

Running title: Nut intake and non-alcoholic fatty liver disease

Word count: 2823

Abstract

Objectives: Nut consumption has been associated with a lower risk of type 2 diabetes, metabolic syndrome, and insulin resistance. However, its effect on the risk of non-alcoholic fatty liver disease (NAFLD) is unknown. Therefore, we investigated the relationship between nut consumption and NAFLD risk.

Setting and participants: We conducted a retrospective case-control study including 534 patients diagnosed with NAFLD and 534 controls matched by sex and age (± 5) from the Affiliated Nanping First Hospital of Fujian Medical University in China.

Main outcome measures: Information on dietary intake was collected using a semi-quantitative food frequency questionnaires and nut consumption was calculated. Nut consumption was categorized using quartiles based on the distribution of daily nut intake of the controls. Binary logistic regression models were used to estimate odds ratio (ORs) and the 95% confidence intervals (CIs) for the association between nut consumption and NAFLD risk.

Results: After adjusting for potential confounding variables, nut consumption was not associated with NAFLD risk in the overall sample. When the fully adjusted model was stratified by sex, a significant inverse association was found between high nut consumption and NAFLD only among the men in the highest quartile (OR = 0.45; 95% CI: 0.27–0.76; $P_{\text{trend}} = 0.01$). The inverse association of nut consumption with NAFLD risk in men remained significant after controlling for other known or suspected risk factors for NAFLD.

Conclusions: Diets with a higher intake of nuts may be associated with a decreased risk of NAFLD, particularly in men.

Strengths and limitations of this study

1. This study had a considerable sample size and several potential confounding variables such as energy intake and physical activity, were taken into account.

2. The study had sufficient power to investigate interactions between nut intake and other risk factors, for which a biologically plausible mechanism may exist.

3. This study was a case-control design, thus the causal association between nut intake and NAFLD could not be precisely identified.

4. This study was a case-control study, recall bias was inevitable and randomized controlled trial studies are therefore required for more accurate results.

Introduction

Non-alcoholic fatty liver disease (NAFLD) is defined as macrovesicular steatosis in $\geq 5\%$ of hepatocytes, in the absence of a secondary cause, such as alcohol or drug use. NAFLD has become a leading cause of chronic liver disease, with a 25% prevalence worldwide¹. Furthermore, a fatty liver is more prevalent in men compared with women². The prevalence of NAFLD among the adults in China's general population is approximately 15% (6.3–27.0%), depending on the population studied³. Many studies suggest that diet and lifestyle may significantly influence the risk of NAFLD^{4,5}. These studies indicate that type 2 diabetes (T2D)⁶, metabolic syndrome (MetS), obesity⁷, physical activity, and a high-fat diet⁴ are associated with an increased risk for the development of NAFLD.

Nuts are nutrient-dense foods with complex matrices rich in unsaturated fatty and other bioactive compounds (e.g., high-quality vegetable protein, fiber, minerals, tocopherols, phytosterols, and phenolic compounds)⁸. The global intake of nuts has increased by 59% over the past decade⁹. China's per capita intake of nuts was 2.2 g/day in 1982, and increased to 3.8g/day in 2012¹⁰. Although they are high in fat and

1
2
3 energy dense, a high intake of nuts has been associated with several health benefits,
4 including reduced risk of cardiovascular disease ¹¹, T2D ¹², MetS¹³, and insulin
5 resistance¹⁴ ¹⁵. Moreover, nuts have antioxidative effects by decreasing lipid
6 peroxidation and protecting against oxidative DNA damage ¹⁶. Beneficial health
7 effects have been attributed to the macronutrient and micronutrient profiles of nuts ¹⁷.

14
15 NAFLD is regarded as the “hepatic manifestation of MetS.” Few studies have
16 assessed the effects of nut intake on NAFLD, despite previous findings of an inverse
17 correlation between high nut consumption and the risk of T2D and cardiovascular
18 disease. In this study, we analyzed the association between nut intake and NAFLD
19 risk and the interactions between nut intake and other established NAFLD risk factors
20 in a large case-control study with a sample of Han adults in China.

28 **Methods**

31 **Study design**

32
33 We conducted the retrospective case-control study in a health examination center at
34 the Affiliated Nanping First Hospital of Fujian Medical University from April 2015 to
35 August 2017. Data were obtained from subjects who underwent routine health
36 examination in the examination center. Patients newly diagnosed with NAFLD using
37 abdominal ultrasonography in accordance with the “Guidelines for the diagnosis and
38 management of nonalcoholic fatty liver disease: update 2010” were included in the
39 study. Hepatic ultrasonography examination was performed by trained
40 ultrasonographers who were blinded to the clinical and laboratory data. Hepatic
41 steatosis was diagnosed by characteristic echo patterns according to conventional
42 criteria, such as the evidence of diffuse hyper-echogenicity of the liver relative to the
43 kidneys, ultrasound beam attenuation, and poor visualization of intrahepatic
44 structures.

Sample size calculation

This study is a case-control design, thus we estimate the sample size based on the Case-control study formula. By consulting the literature¹⁸, we estimate $OR=0.74$, $p_0=0.8$, the calculated sample size was $N_{case}=N_{control}=489$. Finally 1068 subjects (534 cases and 534 controls) were recruited in this study.

Outcome--eligibility of NAFLD cases and controls

All participants were of Chinese Han ethnicity. The cases were newly diagnosed with NAFLD. The exclusion criteria were as follows: (a) daily alcohol intake of >40 g (men) and >20 g (women), (b) a history of other liver diseases including drug-induced liver disease, viral hepatitis, autoimmune hepatitis, total parenteral nutrition, and hepatolenticular degeneration, (c) taking hypolipidemic or weight reduction drugs, (d) age <18 or >70 years, (e) non-resident of Nanping, or (f) not of Han ethnicity. Adults who reported extremely abnormal levels of energy intake (2 511.60 kJ [600 kcal] or 17 581.20 kJ [4 200 kcal] per day for men; 2 093 kJ [500 kcal] or 14,651.00 kJ [3500 kcal] per day for women), and those who did not answer 25 or more food-related items or questions about nut intake on the questionnaire, were excluded from the study.

The controls were randomly selected from the same center during the study period. Their eligibility criteria were identical to those of the cases, except for the requirement of a diagnosis of liver steatosis; they were frequency-matched with cases by age (within 5-yr intervals), gender, ethnicity, and region of origin.

Potential confounders--Data measurements and data collection

Trained interviewers performed a comprehensive medical history on each participant that included eliciting information about their demographic and socio-economic characteristics (e.g., age, gender, education, income, marriage status

1
2
3 and history of diabetes, hypertension, hyperlipidemia and), lifestyle habits (e.g.,
4 smoking, drinking (alcohol), tea drinking, and physical activity), anthropometric
5 assessment (e.g., height, body weight and blood pressure). The data were obtained
6 from participants using structured questionnaires during face-to-face interviews.
7
8
9

10 11 12 **Exposure-Nut consumption**

13
14 Information about participants' typical food consumption was collected using a
15 semi-quantitative food frequency questionnaire that included 110 food items, which
16 was developed and validated in a sample from southern China ¹⁹. Participants were
17 asked to estimate the average frequency of consumption of selected foods using the
18 following response options: rarely, <once/month, 1–3 times/month, 1–2 times/week,
19 3–4 times/week, 5–6 times/week, once/day, twice/day, and >twice/day. Nut intake
20 was defined as the consumption of “peanuts, walnuts, seeds, or other nuts.” Data from
21 a semi-quantitative food frequency questionnaire were used to calculate daily nut and
22 energy intake. Nut consumption was converted to grams/day by multiplying the
23 food-intake frequency by fixed portion sizes. Nutrient intake, such as
24 mono-unsaturated fatty acids (MUFAs) and poly-unsaturated fatty acids (PUFAs)
25 were calculated by multiplying the intake frequency of each food by the nutrient
26 content of the specified portion, and summing the products of all the food items.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 **Statistical analyses**

46
47 Participants' characteristics were analyzed using Pearson's Chi-square test for
48 categorical variables, and Wilcoxon's rank-sum test and ANOVA for continuous
49 variables. Nut consumption was categorized by quartiles based on the distribution of
50 daily nut intake by the controls (Q1-Q4). Binary logistic regression models were used
51 to estimate the odds ratios (ORs) and their 95% confidence intervals (CIs) for the
52 associations between nut consumption and NAFLD risk. To account for the energy
53
54
55
56
57
58
59
60

1
2
3 content of the nut, our initial model adjusted for total energy intake by using the
4 residuals method. The final model adjusted for potential confounders, including age,
5 income, smoking status, educational level, and tea-drinking status, occupational status,
6 marital status, body mass index (BMI), physical activity, and history of diabetes,
7 hypertension, and hyperlipidemia. The final model also adjusted for MUFA and
8 PUFA intake to control for their effects. The selection of covariates for the final
9 model was based on clinical significance, results of previous studies. We tested for
10 linear trends across categories of nut intake by assigning each participant the median
11 value for each category and modeling this value as a continuous variable, consistent
12 with prior studies²⁰⁻²².

13
14 We evaluated the influence of nut consumption across strata of other potential
15 confounders, comparing participants in the highest nut-consumption category to the
16 lowest nut-consumption category(reference). We also analyzed the interactions of nut
17 consumption with age, sex, BMI, smoking status, educational level, tea-drinking
18 status, and other factors. We used the medians of the continuous variables to
19 categorize them and evaluate the interactions. The criteria for statistical significance
20 of the likelihood-ratio test of interaction effects was $P < 0.05$. Statistical analyses
21 were performed using SPSS version 22 (IBM, Armonk, NY, US). All P-values were
22 2-tailed, and $P < 0.05$ was considered statistically significant.

23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 **Patient and public involvement statement**

48
49 The study was approved by the local ethics committees of Fujian Medical
50 University (ethics number 2014096). All methods were performed in accordance with
51 the relevant guidelines and regulations. In addition, each subject gave written informed
52 consent before participation in the study.

Results

Baseline Characteristics

Table 1 presents health-related and demographic characteristics of the NAFLD cases and matched controls. Compared with the controls, the NAFLD cases tended to have a higher BMI, higher total intake of energy, higher MUFA and PUFA consumption, and a higher number of participants with a history of hyperlipidemia among both men and women. Patients with NAFLD had a lower educational level and the men engaged in less physical activity than the controls. No statistically significant associations were found for age, occupational status, income, marital status, smoking status, history of diabetes, or hypertension between the cases and the controls.

Table 1 General characteristics of cases and controls stratified by sex, n(%)

Variables	Men (n=728)			Women(n=340)		
	Cases	Controls(n=364)	P-value ^a	Cases (n=170)	Controls(n=170)	P-value ^a
Age			0.66			0.99
<40	118(32.42)	116(31.87)		25(14.71)	22(12.94)	
40~60	217(59.61)	212(58.24)		123(72.35)	122(71.76)	
≥60	29(7.97)	36(9.89)		22(12.94)	26(15.30)	
Educational level			0.04			0.75
primary school and less than	10(2.75)	23(6.32)		30(17.65)	26(15.29)	
junior middle and high school	147(40.38)	128(35.16)		76(44.70)	74(43.53)	
junior college or above	207(56.87)	213(58.52)		64(37.65)	70(41.18)	
Occupational status			0.39			0.43
mental labour	108(29.67)	104(28.57)		50(29.41)	48(28.24)	
physical labor	86(23.63)	102(28.02)		25(14.71)	34(20.00)	
other	170(46.70)	158(43.41)		95(55.88)	88(51.76)	
Income(yuan/month)			0.35			0.85
<2000	17(4.67)	17(4.67)		15(8.82)	18(10.59)	
2000~3000	87(23.90)	104(28.57)		70(41.18)	70(41.18)	
≥3000	260(71.43)	243(66.76)		85(50.00)	82(48.23)	
Marital status			0.24			0.52
single	45(12.36)	56(15.38)		4(2.35)	6(3.53)	
married or other	319(87.64)	308(84.62)		166(97.65)	164(96.47)	
Smoking status			0.30			0.16
never smoker	199(54.67)	213(58.52)		168(98.82)	170(100)	
smoker	165(45.33)	151(41.48)		2(1.18)	0(0.00)	
Tea-drinking status			0.30			0.01
yes	258(70.88)	245(63.31)		77(45.29)	55(32.35)	
no	106(29.12)	119(32.69)		93(54.71)	115(67.55)	
Physical activity			0.02			0.88
light	175(48.08)	137(37.64)		19(11.18)	19(11.18)	
moderate	100(27.47)	121(33.24)		47(27.64)	43(25.29)	
severe	89(24.45)	106(29.12)		104(61.18)	108(63.53)	
BMI(kg/m ²)			<0.001			<0.001
<18.5	2(0.55)	11(3.02)		1(0.59)	9(5.29)	
18.5~24.0	107(29.40)	257(70.61)		72(42.35)	125(73.53)	
≥24.0	255(70.05)	96(26.37)		97(57.06)	36(21.18)	
History of diabetes			0.67			0.18
yes	12(3.30)	10(2.75)		10(5.88)	5(2.94)	
no	352(96.70)	354(97.25)		160(94.12)	165(94.06)	
History of hypertension			0.85			0.63
yes	15(4.12)	16(4.40)		8(4.71)	10(5.88)	
no	349(95.88)	348(95.60)		162(95.29)	160(94.12)	
History of hyperlipidemia			0.01			<0.001
yes	108(29.67)	77(21.15)		51(30.00)	21(12.35)	
no	256(70.33)	287(78.85)		119(70.00)	149(87.65)	
MUFA intake,g/d ^b	34.10(28.49, 31.39)	26.55(26.55, 36.79)	<0.001	29.99(26.37, 36.37)	28.05(22.40, 31.39)	<0.001
PUFA intake,g/d ^b	26.25(24.04, 23.90)	22.01(22.01, 26.02)	<0.001	24.52(22.11, 27.12)	21.21(18.83, 24.53)	<0.001
Energy intake,kJ/d ^c	10395.64±24989.07	97±2348.76	0.01	7509.73±1650.71	7323.78±1852.97	0.04

^aP-values were calculated by using the Chi-square test for categorical variables and Wilcoxon rank sum test and ANOVA test for continues variables.

^bMedians (IQRs).

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

^cMean(s.d).

The associations of dietary nut intake with NAFLD

The participants' nut consumption is summarized in Table 2. Among the women, those in the NAFLD group consumed a significantly higher amount of nuts (6.80 g/d vs. 2.50 g/d; $P = 0.02$) than those in the control group. No statistically significant differences were found between the cases and controls in the the sample or among the male participants. In order to adjust for potential confounding factors, quartile distributions of dietary nut consumption among the controls were used to categorize the nut intake of all the participants; the results are shown in Table 3. After adjusting for potential confounders, nut consumption was not associated with NAFLD risk among the participants in the sample. When the fully adjusted model was stratified by sex, a significant inverse association was found between nut consumption and NAFLD, but only among the men in the highest quartile (OR = 0.45; 95% CI: 0.27–0.76; $P_{\text{trend}} = 0.01$).

Table 2 Comparison of nut daily intake between the case and the control

Nut intake (g/d)	Case		Control		<i>P</i> -value ^a	<i>P</i> -value ^b
	Median	Quartile	Median	Quartile		
Total population	3.15	1.46-8.80	2.86	1.22-8.98	0.35	0.18
Men	2.68	1.15-8.43	2.86	1.22-8.98	0.36	0.94
Women	6.80	1.75-8.86	2.50	1.07-7.84	0.01	0.02

^a*P*-values:calculated by using Wilcoxon rank sum test;before adjusting for energy.

^b*P*-values :calculated by using Wilcoxon rank sum test; after adjusting for energy by using the residuals methods.

Table 3 Odds ratios (OR) and 95% confidence intervals (CI) for NAFLD in relation to nut intake

Nut intake	Case <i>n</i>	Control <i>n</i>	Crude OR(95%CI)	Model 1 ^a OR(95%CI)	Model 2 ^a OR(95%CI)
Total population ^b	534	534			
Q1	125	133	1	1	1
Q2	112	134	1.30(0.93-1.81)	0.89(0.63-1.26)	0.98(0.65-1.47)
Q3	159	134	1.77(1.29-2.44)	1.26(0.90-1.77)	1.16(0.78-1.72)
Q4	138	133	1.17(0.81-1.68)	1.10(0.78-1.55)	0.85(0.57-1.27)
<i>P</i> for trend*			0.46	0.45	0.07
Men	364	364			
Q1	106	102	1	1	1
Q2	91	79	1.31(0.88-1.94)	0.90(0.60-1.35)	0.92(0.56-1.49)
Q3	74	123	1.81(1.24-2.65)	1.73(1.16-2.57)	1.36(0.85-2.18)
Q4	93	60	1.04(0.66-1.63)	0.67(0.44-1.02)	0.45(0.27-0.76)
<i>P</i> for trend*			0.81	0.04	0.01
Women	170	170			
Q1	23	27	1	1	1
Q2	33	43	1.28(0.69-2.37)	0.90(0.44-1.85)	0.86(0.37-2.02)
Q3	36	60	1.71(0.95-3.08)	0.70(0.35-1.41)	0.56(0.25-1.28)
Q4	78	40	1.41(0.76-2.64)	2.29(1.17-4.49)	1.34(0.59-3.04)
<i>P</i> for trend*			0.36	<0.001	0.12

^aModel 1: Adjusted for total energy intake.

^aModel 2: Adjusted further for age, income, smoking status, educational level, teaing status, occupationanl status, marital status, body mass index, physical activity, the history of diabetes, hypertension and hyperlipidemia, MUFA and PUFA intake.

^b: further adiusted for sex.

**P* for trend: Trend across intake levels with the categorical median.

For total population: Q1, <1.46 g/d; Q2, 1.46-3.15 g/d; Q3, 3.15-8.80 g/d; Q4, ≥8.80 g/d

For men: Q1, <1.15 g/d; Q2, 1.15-2.68 g/d; Q3, 2.68-8.43 g/d; Q4, ≥8.43g/d

For women: Q1, <1.75 g/d; Q2, 1.75-6.80 g/d; Q3, 6.80-8.86 g/d; Q4, ≥8.86 g/d.

Stratified Analyses

In the stratified analysis, the inverse association between total-nut consumption and NAFLD risk was consistent across strata of age, sex, BMI, educational level, income, physical activity, smoking, tea drinking, and history of diabetes, hypertension, and hyperlipidemia. In addition to the association between nut consumption and NAFLD in men, we also found the highest nut-consumption category was associated

1
2
3 with a lower risk of developing NAFLD than the reference (OR = 0.53; 95% CI:
4 0.31–0.93) among the participants who engaged in light and moderate physical
5 activity. No significant interactions of total nut consumption and the potentially
6 confounding effects of NAFLD risk factors were identified (Figure 1).
7
8
9
10

11 **Discussion**

12
13
14 In this case-control study, we found a significant inverse relationship between
15 high nut consumption and NAFLD risk among the males, but found either no or
16 unclear associations among the females and the overall sample. Moreover, the
17 associations seemed to be independent of other predictors, including diet and lifestyle
18 factors. The effect of nut consumption remained among men after controlling for
19 other known or suspected risk factors for developing NAFLD. Furthermore, no
20 significant interactions between nut consumption and the potential modifying effects
21 of NAFLD risk factors were identified. To the best of our knowledge, this was the
22 first study to assess the association between nut consumption and the risk of NAFLD
23 in a Chinese sample.
24
25
26
27
28
29
30
31
32
33
34
35
36

37 Our results are consistent with a previous study conducted in Korea, which found
38 that a low intake of nuts and seeds (OR = 3.66; $P_{\text{trend}} = 0.007$) was associated with a
39 significantly higher risk of developing NAFLD among male participants, but not
40 among females²³. Although another case-control study found an association between
41 a high intake of nuts with a lower likelihood of NAFLD, after adjusting for the
42 confounders age, sex, waist circumference, and the values of the homeostasis model
43 assessment of insulin resistance (OR = 0.61; 95% CI: 0.38–0.98), the association
44 disappeared after further adjustment for adiponectin and TNF- α (OR = 0.72; 95% CI:
45 0.41–1.25)¹⁸. However, the study did not examine nut intake separately; therefore,
46 the results cannot be directly compared with those of our study. Although the results
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 of our study suggest nuts may play a protective role in the development of NAFLD in
4
5 males, a significant association between nut intake and the risk of NAFLD was not
6
7 found in females. NAFLD has been regarded as the “hepatic manifestation of MetS”;
8
9 therefore, our findings are indirectly supported by several studies showing an inverse
10
11 correlation between high nut intake and the risk of T2D and cardiovascular disease,
12
13 which share common metabolic parameters with NAFLD ²⁴⁻²⁶. Nevertheless, the
14
15 relationship between nut intake and NAFLD warrants further exploration, and
16
17 additional studies are needed to examine gender differences in the association
18
19 between nut consumption and NAFLD, and its’ possible mechanisms should be
20
21 explored.
22
23
24
25

26
27 Several biological pathways have been proposed to explain the association
28
29 between nut intake and NAFLD risk. Ellagic acid, a natural antioxidant polyphenol
30
31 found in nuts, can suppress oxidative stress and inflammation ²⁷ and improve hepatic
32
33 insulin sensitivity and lipid metabolism ²⁸. Vitamin E and selenium in almonds and
34
35 walnuts, as well as folic acid and resveratrol in pine nuts, have been reported to have
36
37 beneficial effects on NAFLD. Numerous trials testing the therapeutic value of vitamin
38
39 E in NAFLD prevention found that Vitamin E significantly improved liver function
40
41 and histologic changes by significantly reducing aspartate aminotransferase, alanine
42
43 aminotransferase, steatosis, and inflammation in patients with NAFLD/non-alcoholic
44
45 steatohepatitis (NASH) ²⁹. Selenium is an antioxidant agent, and selenium deficiency
46
47 is associated with insulin resistance in patients with chronic liver disease ³⁰. Folate
48
49 plays an essential role in lipid metabolism and folic acid supplementation can
50
51 attenuate steatosis and improve oxidative stress in rodent models of NAFLD. Folate
52
53 can also blunt the increase of inflammatory cytokines secreted by immune cells ³¹.
54
55 Resveratrol has antioxidant, anti-apoptotic, and anti-inflammatory properties in
56
57
58
59
60

1
2
3 NAFLD patients ³². Nuts, which are known to be rich in unsaturated fatty acids, are
4 especially rich in n-3 PUFAs, a source of alpha-linolenic acid, which lowers LDL
5 cholesterol ³³, and has been found to have beneficial effects on NAFLD ³⁴. Each type
6 of nut has many nutrients and phytochemicals that may be beneficial to health, and it
7 is likely that unknown salubrious effects of nuts may be related to NAFLD prevention.
8 Moreover, many studies have shown a beneficial association between high nut intake
9 and decreased risk of obesity ³⁵, T2D ³⁶, and MetS ³⁷, which are risk factors for
10 NAFLD.
11
12

13
14
15 Our study has both strengths and limitations. The first strength is the large sample
16 size, which may have reduced type II errors. Second, the collection of data using
17 face-to-face interviews and a semi-quantitative food frequency questionnaire, which
18 elicited extensive information on anthropometrics and lifestyle factors, allowed us to
19 adjust for confounding factors. Finally, the study had sufficient power to investigate
20 interactions between nut intake and other risk factors, for which a biologically
21 plausible mechanism may exist. Nonetheless, several limitations should be considered
22 when interpreting the study's findings. First, although we accounted for a wide range
23 of socioeconomic characteristics and lifestyle factors, we cannot exclude the effects of
24 unknown or poorly measured confounding variables or residual confounding
25 attributable to other dietary/lifestyle factors, which might have influenced the
26 observed associations. However, the associations persisted even after controlling for
27 known and suspected predictors of NAFLD. Second, the intake of nuts was assessed
28 by asking about using one question; therefore, we could not investigate the effects of
29 different types of nuts, such as peanuts and walnuts, which contain different amounts
30 of energy, fat content, and other nutrients³⁸. Third, categorization of the intake of nuts
31 in quartiles may lead to bias and inefficiency. Fourth, we did not consider
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 manufacturing methods (e.g., raw, roasted, or boiled) or extra ingredients (e.g., sugar,
4 salt, seasoning). Different preparation methods before and after roasting, the amount
5 of time roasted, and the temperature used can affect the nutrient composition and
6 ingredients in the nuts^{39 40}. What's more, the item 'nuts' in the FFQ used in this study
7 cannot represent all nuts, because it only included peanuts, walnuts, seeds. For this
8 reason, direct comparisons with the results of other studies may be difficult. Fifth,
9 because we used a case-control study design, recall bias is an inherent limitation.
10 People who are health-conscious may over-report or under-report some food items.
11 However, the protective effect of nuts on NAFLD was not generally known at the
12 time of the survey, and thus, should be unrelated to recall bias. In addition, the
13 stratified analyses was not corrected for multiple testing, which may inflate the risk
14 for type I error. Finally, due to the small number of participants in the highest
15 nut-intake category, we cannot rule out the possibility that some of our results are due
16 to chance. However, the associations were consistent in the analyses stratified by
17 some of the other factors, which reduces the likelihood of chance findings. In these
18 stratified analyses, the statistical power needed to detect differences was limited by
19 the sample size, and such analyses should be considered exploratory.

20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42 Our study had a retrospective design, which is lower on the evidence hierarchy than
43 prospective studies. Nevertheless, case-control studies can provide evidence
44 supporting the general relationship between diet and NAFLD, as there currently are
45 no available prospective studies.

46
47
48
49
50
51 In conclusion, this case-control study indicated that high nut intake was associated
52 with a significantly reduced risk of NAFLD among Han men in China. However, no
53 relationship was found between total nut intake and NAFLD risk among the Han
54 women. Our data contribute to the growing evidence showing that a relatively simple
55
56
57
58
59
60

1
2
3 prevention strategy of incorporating a modest amount of nuts in the diet may
4
5 contribute to maintaining good health at both the individual and population levels.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Acknowledgements

We thank all study participants for their cooperation. We also thank our staff for recruiting participants and for their technical assistance.

Contributors

BBC and YH are joint first authors. XEP obtained funding. XEP, XL and SHX designed the study. XTP, JHY, YFL and WJL collected the data. BBC and YH were involved in data cleaning and verification. BBC and XTP analyzed the data. BBC and YH drafted the manuscript. XEP, YFL and JHY contributed to the interpretation of the results and critical revision of the manuscript for important intellectual content and approved the final version of the manuscript. All authors have read and approved the final manuscript.

Data sharing

No additional data are available.

Conflict of Interest

The authors declare that they have no conflict of interest.

Funding

This work was supported by the National Natural Science Foundation of China [grant number 81473047], the Training Program Foundation for Middle-aged and Young Talents from the Sanitation System of Fujian Province [grant number 2014-ZQN-ZD-23], and the Joint Innovation Project of Science and Technology of Fujian Province [grant number 2017Y9104].

References

1. Maurice J, Manousou P. Non-alcoholic fatty liver disease. *Clin Med (Lond)* 2018;**18**(3):245-50. doi: 10.7861/clinmedicine.18-3-245
2. Rietman A, Sluik D, Feskens E, *et al.* Associations between dietary factors and markers of NAFLD in a general Dutch adult population. *Eur J Clin Nutr* 2018;**72**(1):117-23. doi: 10.1038/ejcn.2017.148
3. Fan J. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. *J Gastroenterol Hepatol* 2013;**28** Suppl 1:11-17. doi: 10.1111/jgh.12036
4. Katsagoni C, Georgoulis M, Papatheodoridis G, *et al.* Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. *Metab Clin Exp* 2017;**68**:119-32. doi: 10.1016/j.metabol.2016.12.006
5. Zelber-Sagi S, Salomone F, Mlynarsky L. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanisms. *Liver Int* 2017;**37**(7):936-49. doi: 10.1111/liv.13435
6. Kosmidou M, Milionis H. Diabetes mellitus and non-alcoholic fatty liver disease: the thread of Ariadne. *Minerva Endocrinol* 2017;**42**(2):109-21. doi: 10.23736/S0391-1977.16.02562-1
7. Petrović G, Bjelaković G, Benedeto-Stojanov D, *et al.* Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound. *Vojnosanit Pregl* 2016;**73**(10):910-20. doi: 10.2298/vsp150514093p

- 1
2
3
4 8. Ros E. Health benefits of nut consumption. *Nutrients* 2010;**2(7)**:652-82. doi:
5
6 10.3390/nu2070652
7
8
9 9. Lee J, Shin A, Oh JH, *et al.* The relationship between nut intake and risk of
10
11 colorectal cancer: a case control study. *Nutr J* 2018;**17(1)**:37. doi:
12
13 10.1186/s12937-018-0345-y
14
15
16 10. Lahong J, Dongmei Y, Xiaoli X. Status and variation trend of nut intake among
17
18 Chinese residents,2010-2012. *Chin J Public Health* 2017;**33(6)**:916-18.
19
20
21 11. Larsson S, Drea N, Björck M, *et al.* Nut consumption and incidence of seven
22
23 cardiovascular diseases. *Heart* 2018 doi: 10.1136/heartjnl-2017-312819
24
25
26 12. Asghari G, Ghorbani Z, Mirmiran P, *et al.* Nut consumption is associated with
27
28 lower incidence of type 2 diabetes: The Tehran Lipid and Glucose Study.
29
30
31 *Diabetes Metab* 2017;**43(1)**:18-24. doi: 10.1016/j.diabet.2016.09.008
32
33
34 13. O'Neil C, Fulgoni V, Nicklas T. Tree Nut consumption is associated with better
35
36 adiposity measures and cardiovascular and metabolic syndrome health risk
37
38 factors in U.S. Adults: NHANES 2005-2010. *Nutr J* 2015;**14**:64. doi:
39
40
41 10.1186/s12937-015-0052-x
42
43
44 14. Casas-Agustench P, López-Uriarte P, Bulló M, *et al.* Effects of one serving of
45
46 mixed nuts on serum lipids, insulin resistance and inflammatory markers in
47
48 patients with the metabolic syndrome. *Nutr Metab Cardiovasc Dis*
49
50
51 2011;**21(2)**:126-35. doi: 10.1016/j.numecd.2009.08.005
52
53
54 15. Hernández-Alonso P, Salas-Salvadó J, Baldrich-Mora M, *et al.* Beneficial effect
55
56 of pistachio consumption on glucose metabolism, insulin resistance,
57
58
59
60

- 1
2
3
4 inflammation, and related metabolic risk markers: a randomized clinical trial.
5
6 *Diabetes Care* 2014;**37(11)**:3098-105. doi: 10.2337/dc14-1431
7
8
- 9 16. Grosso G, Yang J, Marventano S, *et al.* Nut consumption on all-cause,
10
11 cardiovascular, and cancer mortality risk: a systematic review and
12
13 meta-analysis of epidemiologic studies. *Am J Clin Nutr* 2015;**101(4)**:783-93.
14
15
16 doi: 10.3945/ajcn.114.099515
17
18
- 19 17. Dreher M, Maher C, Kearney P. The traditional and emerging role of nuts in
20
21 healthful diets. *Nutr Rev* 1996;**54(8)**:241-45.
22
23
- 24 18. Katsagoni C, Georgoulis M, Papatheodoridis G, *et al.* Associations Between
25
26 Lifestyle Characteristics and the Presence of Nonalcoholic Fatty Liver
27
28 Disease: A Case-Control Study. *Metab Syndr Relat Disord* 2017;**15(2)**:72-79.
29
30
31 doi: 10.1089/met.2016.0105
32
33
- 34 19. Ke L, Toshiro T, Fengyan S, *et al.* Relative validity of a semi-quantitative food
35
36 frequency questionnaire versus 3 day weighed diet records in middle-aged
37
38 inhabitants in Chaoshan area, China. *Asian Pac J Cancer Prev*
39
40
41 2005;**6(3)**:376-81. [published Online First: 2005/10/21]
42
43
44
- 45 20. T F, S Z, D N, *et al.* Nut Consumption and Survival in Patients With Stage III
46
47 Colon Cancer: Results From CALGB 89803 (Alliance). *Journal of clinical*
48
49 *oncology : official journal of the American Society of Clinical Oncology*
50
51
52 2018;**36(11)**:1112-20. doi: 10.1200/JCO.2017.75.5413
53
54
- 55 21. MA F, K S, D N, *et al.* Sugar-sweetened beverage intake and cancer recurrence
56
57
58 and survival in CALGB 89803 (Alliance). *PloS one* 2014;**9(6)**:e99816. doi:
59
60

- 1
2
3
4 10.1371/journal.pone.0099816
5
6
7 22. JA M, K S, D N, *et al.* Dietary glycemic load and cancer recurrence and survival
8
9 in patients with stage III colon cancer: findings from CALGB 89803. *Journal*
10
11 *of the National Cancer Institute* 2012;**104(22)**:1702-11. doi:
12
13 10.1093/jnci/djs399
14
15
16
17 23. Han JM, Jo AN, Lee SM, *et al.* Associations between intakes of individual
18
19 nutrients or whole food groups and non-alcoholic fatty liver disease among
20
21 Korean adults. *Journal of Gastroenterology and Hepatology*
22
23 2014;**29(6)**:1265-72. doi: 10.1111/jgh.12520
24
25
26
27 24. Edens M, Kuipers F, Stolk R. Non-alcoholic fatty liver disease is associated with
28
29 cardiovascular disease risk markers. *Obes Rev* 2009;**10(4)**:412-19. doi:
30
31 10.1111/j.1467-789X.2009.00594.x
32
33
34
35 25. Lonardo A, Ballestri S, Guaraldi G, *et al.* Fatty liver is associated with an
36
37 increased risk of diabetes and cardiovascular disease - Evidence from three
38
39 different disease models: NAFLD, HCV and HIV. *World J Gastroenterol*
40
41 2016;**22(44)**:9674-93. doi: 10.3748/wjg.v22.i44.9674
42
43
44
45 26. Gastaldelli A. Insulin resistance and reduced metabolic flexibility: cause or
46
47 consequence of NAFLD? *Clin Sci* 2017;**131(22)**:2701-04. doi:
48
49 10.1042/CS20170987
50
51
52
53 27. Panchal SK, Ward L, Brown L. Ellagic acid attenuates high-carbohydrate, high-fat
54
55 diet-induced metabolic syndrome in rats. *Eur J Nutr* 2013;**52(2)**:559-68. doi:
56
57 10.1007/s00394-012-0358-9
58
59
60

- 1
2
3
4 28. Polce S, Burke C, França L, *et al.* Ellagic Acid Alleviates Hepatic Oxidative
5
6 Stress and Insulin Resistance in Diabetic Female Rats. *Nutrients*
7
8
9 2018;**10(5)**:1-15. doi: 10.3390/nu10050531
10
11
12 29. Sato K, Gosho M, Yamamoto T, *et al.* Vitamin E has a beneficial effect on
13
14 nonalcoholic fatty liver disease: a meta-analysis of randomized controlled
15
16 trials. *Nutrition* 2015;**31(7-8)**:923-30. doi: 10.1016/j.nut.2014.11.018
17
18
19 30. Himoto T, Yoneyama H, Kurokohchi K, *et al.* Selenium deficiency is associated
20
21 with insulin resistance in patients with hepatitis C virus-related chronic liver
22
23 disease. *Nutr Res* 2011;**31(11)**:829-35. doi: 10.1016/j.nutres.2011.09.021
24
25
26 31. Sid V, Siow Y, O K. Role of folate in nonalcoholic fatty liver disease. *Can J*
27
28 *Physiol Pharmacol* 2017;**95(10)**:1141-48. doi: 10.1139/cjpp-2016-0681
29
30
31
32 32. Hajjighasem A, Farzanegi P, Mazaheri Z. Effects of combined therapy with
33
34 resveratrol, continuous and interval exercises on apoptosis, oxidative stress,
35
36 and inflammatory biomarkers in the liver of old rats with non-alcoholic fatty
37
38 liver disease. *Arch Physiol Biochem* 2018:1-8. doi:
39
40 0.1080/13813455.2018.1441872
41
42
43
44 33. Jeznach-Steinhagen A, Ostrowska J, Czerwonogrodzka-Senczyna A, *et al.*
45
46 [Dietary recommendation for non-alcoholic fatty liver disease]. *Pol Merkur*
47
48 *Lekarski* 2017;**43(258)**:281-86.
49
50
51
52
53 34. Musa-Veloso K, Venditti C, Lee H, *et al.* Systematic review and meta-analysis of
54
55 controlled intervention studies on the effectiveness of long-chain omega-3
56
57 fatty acids in patients with nonalcoholic fatty liver disease. *Nutr Rev*
58
59
60

- 2018;**0(0)**:1-22. doi: 10.1093/nutrit/nuy022
35. Mohammadifard N, Yazdekhashti N, Stangl G, *et al.* Inverse association between the frequency of nut consumption and obesity among Iranian population: Isfahan Healthy Heart Program. *Eur J Nutr* 2015;**54(6)**:925-31. doi: 10.1007/s00394-014-0769-x
36. Hernández-Alonso P, Camacho-Barcia L, Bulló M, *et al.* Nuts and Dried Fruits: An Update of Their Beneficial Effects on Type 2 Diabetes. *Nutrients* 2017;**9(7)**:673. doi: 10.3390/nu9070673
37. Hosseinpour-Niazi S, Hosseini S, Mirmiran P, *et al.* Prospective Study of Nut Consumption and Incidence of Metabolic Syndrome: Tehran Lipid and Glucose Study. *Nutrients* 2017;**9(10)**:1056. doi: 10.3390/nu9101056
38. Wu L, Wang Z, Zhu J, *et al.* Nut consumption and risk of cancer and type 2 diabetes: a systematic review and meta-analysis. *Nutr Rev* 2015;**73(7)**:409-25. doi: 10.1093/nutrit/nuv006
39. Schlörmann W, Birringer M, Böhm V, *et al.* Influence of roasting conditions on health-related compounds in different nuts. *Food Chem* 2015;**180**:77-85. doi: 10.1016/j.foodchem.2015.02.017
40. Hosseini Bai S, Darby I, Nevenimo T, *et al.* Effects of roasting on kernel peroxide value, free fatty acid, fatty acid composition and crude protein content. *PLoS ONE* 2017;**12(9)**:e0184279. doi: 10.1371/journal.pone.0184279

Figure legends

Figure 1. Odds ratios (OR) and 95% CIs for NAFLD across the strata of various factors.

The forest plot represents the ORs of the comparison of the lowest nut-intake category versus the highest nut-intake category, adjusting for age, income, smoking status, educational level, tea-drinking status, occupational status, marital status, BMI, physical activity, history of diabetes, hypertension and hyperlipidemia, total energy intake, and MUFA and PUFA intake. P -values are two-tailed; P_{inter} indicates P for the interaction between strata and nut intake; P_{trend} indicates P for the trend across levels of nut intake.




Figure 1. Odds ratios (OR) and 95% CIs for NAFLD across the strata of various factors. The forest plot represents the ORs of the comparison of the lowest nut-intake category versus the highest nut-intake category, adjusting for age, income, smoking status, educational level, tea-drinking status, occupational status, marital status, BMI, physical activity, history of diabetes, hypertension and hyperlipidemia, total energy intake, and MUFA and PUFA intake. P-values are two-tailed; Pinter indicates P for the interaction between strata and nut intake; Ptrend indicates P for the trend across levels of nut intake.

148x159mm (96 x 96 DPI)

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *case-control studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	5
		(b) For matched studies, give matching criteria and the number of controls per case	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-6
Bias	9	Describe any efforts to address potential sources of bias	7

Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6-7
		(b) Describe any methods used to examine subgroups and interactions	7
		(c) Explain how missing data were addressed	
		(d) If applicable, explain how matching of cases and controls was addressed	5
		(e) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8-9
		(b) Indicate number of participants with missing data for each variable of interest	
Outcome data	15*	Report numbers in each exposure category, or summary measures of exposure	8-9
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-10
		(b) Report category boundaries when continuous variables were categorized	10-11

		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	11
Discussion			
Key results	18	Summarise key results with reference to study objectives	12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	15
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	17

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Association between nut intake and Non-alcoholic fatty liver disease risk: a retrospective case-control study in a sample of Chinese Han adults

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-028961.R2
Article Type:	Research
Date Submitted by the Author:	25-Jun-2019
Complete List of Authors:	Chen, Bing bing; Fujian Medical University, Han, Ying; The First Affiliated Hospital of Fujian Medical University Pan, Xinting; Department of Epidemiology and Health Statistics, Fujian Provincial Key Laboratory of Environment Factors and Cancer, School of Public Health, Fujian Medical University Yan, Jianhui; Department of Epidemiology and Health Statistics, Fujian Provincial Key Laboratory of Environment Factors and Cancer, School of Public Health, Fujian Medical University Liu, Wenjuan; Department of Epidemiology and Health Statistics, Fujian Provincial Key Laboratory of Environment Factors and Cancer, School of Public Health, Fujian Medical University li, yangfan; Department of Epidemiology and Health Statistics, Fujian Provincial Key Laboratory of Environment Factors and Cancer, School of Public Health, Fujian Medical University, Fujian, China, ; lin, xu; Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fujian, China xu, shanghua; Department of Cardiology, Affiliated Nanping First Hospital, Fujian Medical University, Nanping, China Peng, Xian-E; Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fujian,
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Nutrition and metabolism, Public health
Keywords:	EPIDEMIOLOGY, NUTRITION & DIETETICS, Lipid disorders < DIABETES & ENDOCRINOLOGY

SCHOLARONE™
Manuscripts

1
2
3 **Association between nut intake and Non-alcoholic fatty liver disease risk: a**
4 **retrospective case-control study in a sample of Chinese Han adults**
5
6

7 Bingbing Chen^{1#}, Ying Han^{2#}, Xinting Pan¹, Jianhui Yan¹, Wenjuan Liu¹, Yangfan Li¹, Xu Lin³,
8 Shanghua Xu⁴, Xian-e Peng^{1,3*}
9

10 ¹ Department of Epidemiology and Health Statistics, Fujian Provincial Key
11 Laboratory of Environment Factors and Cancer, School of Public Health, Fujian
12 Medical University, Fujian, China;
13
14

15
16
17 ² The First Affiliated Hospital of Fujian Medical University
18

19 ³ Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian
20 Medical University, Fujian, China;
21
22

23
24 ⁴ Department of Cardiology, Affiliated Nanping First Hospital, Fujian Medical
25 University, Nanping, China
26
27

28 [#] Both authors contributed equally to this work.
29

30 ^{*} Corresponding author. Xian-E Peng, Department of Epidemiology and Health
31 Statistics, Fujian Provincial Key Laboratory of Environment Factors and Cancer,
32 School of Public Health, Fujian Medical University, Fujian, China, 3501018
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Phone: +86-0591 22862648; E-mail: fmuxe@163.com

Running title: Nut intake and non-alcoholic fatty liver disease

Word count: 3055

Abstract

Objectives: Nut consumption has been associated with a lower risk of type 2 diabetes, metabolic syndrome, and insulin resistance. However, its effect on the risk of non-alcoholic fatty liver disease (NAFLD) is unknown. Therefore, we investigated the relationship between nut consumption and NAFLD risk.

Setting and participants: We conducted a retrospective case-control study including 534 patients diagnosed with NAFLD and 534 controls matched by sex and age (± 5) from the Affiliated Nanping First Hospital of Fujian Medical University in China.

Main outcome measures: Information on dietary intake was collected using a semi-quantitative food frequency questionnaires and nut consumption was calculated. Nut consumption was categorized using quartiles based on the distribution of daily nut intake of the controls. Binary logistic regression models were used to estimate odds ratio (ORs) and the 95% confidence intervals (CIs) for the association between nut consumption and NAFLD risk.

Results: After adjusting for potential confounding variables, nut consumption was not associated with NAFLD risk in the overall sample. When the fully adjusted model was stratified by sex, a significant inverse association was found between high nut consumption and NAFLD only among the men in the highest quartile (OR = 0.43; 95% CI: 0.26–0.71; $P_{\text{trend}} = 0.01$). The inverse association of nut consumption with NAFLD risk in men remained significant after controlling for other known or suspected risk factors for NAFLD.

Conclusions: Diets with a higher intake of nuts may be associated with a decreased risk of NAFLD, particularly in men.

Strengths and limitations of this study

1. In this study, several potential confounding variables such as energy intake and physical activity, were taken into account.

2. The study had tried to investigate interactions between nut intake and other risk factors, for which a biologically plausible mechanism may exist.

3. This study was a case-control design, thus the causal association between nut intake and NAFLD could not be precisely identified.

4. This study was a case-control study, recall bias was inevitable and randomized controlled trial studies are therefore required for more accurate results.

Introduction

Non-alcoholic fatty liver disease (NAFLD) is defined as macrovesicular steatosis in $\geq 5\%$ of hepatocytes, in the absence of a secondary cause, such as alcohol or drug use. NAFLD has become a leading cause of chronic liver disease, with a 25% prevalence worldwide¹. Furthermore, a fatty liver is more prevalent in men compared with women². The prevalence of NAFLD among the adults in China's general population is approximately 15% (6.3–27.0%), depending on the population studied³. Many studies suggest that diet and lifestyle may significantly influence the risk of NAFLD^{4,5}. These studies indicate that type 2 diabetes (T2D)⁶, metabolic syndrome (MetS), obesity⁷, physical activity, and a high-fat diet⁴ are associated with an increased risk for the development of NAFLD.

Nuts are nutrient-dense foods with complex matrices rich in unsaturated fatty and other bioactive compounds (e.g., high-quality vegetable protein, fiber, minerals, tocopherols, phytosterols, and phenolic compounds)⁸. The global intake of nuts has increased by 59% over the past decade⁹. China's per capita intake of nuts was 2.2 g/day in 1982, and increased to 3.8g/day in 2012¹⁰. Although they are high in fat and

1
2
3 energy dense, a high intake of nuts has been associated with several health benefits,
4 including reduced risk of cardiovascular disease ¹¹, T2D ¹², MetS¹³, and insulin
5 resistance¹⁴ ¹⁵.Moreover, nuts have antioxidative effects by decreasing lipid
6 peroxidation and protecting against oxidative DNA damage ¹⁶. Beneficial health
7 effects have been attributed to the macronutrient and micronutrient profiles of nuts ¹⁷.

14 NAFLD is regarded as the “hepatic manifestation of MetS.” Few studies have
15 assessed the effects of nut intake on NAFLD, despite previous findings of an inverse
16 correlation between high nut consumption and the risk of T2D and cardiovascular
17 disease. In this study, we analyzed the association between nut intake and NAFLD
18 risk and the interactions between nut intake and other established NAFLD risk factors
19 in a large case-control study with a sample of Han adults in China.

28 **Methods**

31 **Patient and public involvement statement**

32 The study was approved by the local ethics committees of Fujian Medical University
33 (ethics number 2014096). All subjects underwent abdominal ultrasound and blood
34 biochemical tests. Once cases and controls have been linked to the NAFLD, a letter of
35 invitation and information about the study will be sent to each potential case and
36 control to obtain consent. All methods were performed in accordance with the
37 relevant guidelines and regulations. The subjects were not involved in the design and
38 planning of the study .They were not involved in the recruitment to and conduct of the
39 study.

51 **Study design**

52 We conducted the retrospective case-control study in a health examination cent
53 er at the Affiliated Nanping First Hospital of Fujian Medical University from
54 April 2015 to August 2017. Data were obtained from subjects who underwent
55
56
57
58
59
60

1
2
3 routine health examination in the examination center. Patients newly diagnosed
4 with NAFLD using abdominal ultrasonography in accordance with the “Guideli
5 nes for the diagnosis and management of nonalcoholic fatty liver disease: update
6 2010” were included in the study. Hepatic ultrasonography examination was pe
7 rformed by trained ultrasonographers who were blinded to the clinical and labo
8 ratory data. Hepatic steatosis was diagnosed by characteristic echo patterns acc
9 ording to conventional criteria, such as the evidence of diffuse hyper-echogenic
10 ity of the liver relative to the kidneys, ultrasound beam attenuation, and poor
11 visualization of intrahepatic structures.
12
13
14
15
16
17
18
19
20
21
22

23 **Sample size calculation**

24
25 This study is a case-control design, thus we estimate the sample size based on the
26 case-control study formula: $n = 2\bar{p}\bar{q}(z_{\alpha} + z_{\beta})^2 / (p_1 - p_0)^2$, $p_1 = \frac{p_0 RR}{1 + p_0(RR - 1)}$,
27
28 $\bar{p} = 0.5 \times (p_1 + p_0)$, $\bar{q} = 1 - \bar{p}$. By consulting the literature¹⁸, we estimate $OR_{\text{nut intake}} =$
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
0.72, $p_0 = 0.50$, $\alpha = 0.05$, $\beta = 0.20$, the calculated sample size was $N_{\text{case}} = N_{\text{control}} = 609$.
Finally 1068 subjects (534 cases and 534 controls) were recruited in this study.

40 **Outcome--eligibility of NAFLD cases and controls**

41
42 All participants were of Chinese Han ethnicity. The cases were newly diagnosed
43 with NAFLD. The exclusion criteria were as follows: (a) daily alcohol intake of >40 g
44 (men) and >20 g (women), (b) a history of other liver diseases including drug-induced
45 liver disease, viral hepatitis, autoimmune hepatitis, total parenteral nutrition, and
46 hepatolenticular degeneration, (c) taking hypolipidemic or weight reduction drugs, (d)
47 age <18 or >70 years, (e) non-resident of Nanping, or (f) not of Han ethnicity. Adults
48 who reported extremely abnormal levels of energy intake (2 511.60 kJ [600 kcal] or
49
50
51
52
53
54
55
56
57
58
59
60
17 581.20 kJ [4 200 kcal] per day for men; 2 093 kJ [500 kcal] or 14,651.00 kJ [3500

1
2
3 kcal] per day for women), and those who did not answer 25 or more food-related
4 items or questions about nut intake on the questionnaire, were excluded from the
5 study.
6
7
8
9

10 The controls were randomly selected from the same center during the study period.
11 Their eligibility criteria were identical to those of the cases, except for the
12 requirement of a diagnosis of liver steatosis; they were frequency-matched with cases
13 by age (within 5-yr intervals), gender, ethnicity, and region of origin.
14
15
16
17
18

19 **Potential confounders--Data measurements and data collection**

20
21 Trained interviewers performed a comprehensive medical history on each
22 participant that included eliciting information about their demographic and
23 socio-economic characteristics (e.g., age, gender, education, income, marriage status
24 and history of diabetes, hypertension, hyperlipidemia and), lifestyle habits (e.g.,
25 smoking, drinking (alcohol), tea drinking, and physical activity), anthropometric
26 assessment (e.g., height, body weight and blood pressure). The data were obtained
27 from participants using structured questionnaires during face-to-face interviews.
28
29
30
31
32
33
34
35
36

37 **Exposure-Nut consumption**

38
39 Information about participants' typical food consumption was collected using a
40 semi-quantitative food frequency questionnaire that included 110 food items, which
41 was developed and validated in a sample from southern China ¹⁹. Participants were
42 asked to estimate the average frequency of consumption of selected foods using the
43 following response options: rarely, <once/month, 1–3 times/month, 1–2 times/week,
44 3–4 times/week, 5–6 times/week, once/day, twice/day, and >twice/day. Nut intake
45 was defined as the consumption of “peanuts, walnuts, seeds, or other nuts.” Data from
46 a semi-quantitative food frequency questionnaire were used to calculate daily nut and
47 energy intake. Nut consumption was converted to grams/day by multiplying the
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 food-intake frequency by fixed portion sizes. Nutrient intake, such as
4 mono-unsaturated fatty acids (MUFAs) and poly-unsaturated fatty acids (PUFAs)
5 were calculated by multiplying the intake frequency of each food by the nutrient
6 content of the specified portion, and summing the products of all the food items.
7
8
9
10
11

12 **Statistical analyses**

13
14 Participants' characteristics were analyzed using Pearson's Chi-square test for
15 categorical variables, and Wilcoxon's rank-sum test and ANOVA for continuous
16 variables. Nut consumption was categorized by quartiles based on the distribution of
17 daily nut intake by the controls (Q1-Q4). Binary logistic regression models were used
18 to estimate the odds ratios (ORs) and their 95% confidence intervals (CIs) for the
19 associations between nut consumption and NAFLD risk. To account for the energy
20 content of the nut, our initial model adjusted for total energy intake by using the
21 residuals method. The final model adjusted for potential confounders, including age,
22 income, smoking status, educational level, and tea-drinking status, occupational status,
23 marital status, body mass index (BMI), physical activity, and history of diabetes,
24 hypertension, and hyperlipidemia. In order to reflect the matching protocol, when
25 adjust for age, we entered a term for residual age into the regression analysis²⁰. The
26 final model also adjusted for MUFA and PUFA intake to control for their effects. The
27 selection of covariates for the final model was based on clinical significance, results
28 of previous studies. We tested for linear trends across categories of nut intake by
29 assigning each participant the median value for each category and modeling this value
30 as a continuous variable, consistent with prior studies²¹⁻²³.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54 We evaluated the influence of nut consumption across strata of other potential
55 confounders, comparing participants in the highest nut-consumption category to the
56 lowest nut-consumption category(reference). We also analyzed the interactions of nut
57
58
59
60

1
2
3 consumption with age, sex, BMI, smoking status, educational level, tea-drinking
4 status, and other factors. We used the medians of the continuous variables to
5
6 categorize them and evaluate the interactions. The criteria for statistical significance
7
8 of the likelihood-ratio test of interaction effects was $P < 0.05$. Statistical analyses
9
10 were performed using SPSS version 22 (IBM, Armonk, NY, US). All P-values were
11
12
13
14
15 2-tailed, and $P < 0.05$ was considered statistically significant.

16 17 **Results**

18 19 **Baseline Characteristics**

20
21 Table 1 presents health-related and demographic characteristics of the NAFLD
22 cases and matched controls. Compared with the controls, the NAFLD cases tended to
23
24 have a higher BMI, higher total intake of energy, higher MUFA and PUFA
25
26 consumption, and a higher number of participants with a history of hyperlipidemia
27
28 among both men and women. Patients with NAFLD had a lower educational level and
29
30 the men engaged in less physical activity than the controls. No statistically significant
31
32 associations were found for age, occupational status, income, marital status, smoking
33
34 status, history of diabetes, or hypertension between the cases and the controls.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 General characteristics of cases and controls stratified by sex, n(%)

Variables	Men (n=728)			Women (n=340)		
	Cases	Controls (n=364)	P-value ^a	Cases (n=170)	Controls (n=170)	P-value ^a
Age			0.66			0.99
<40	118(32.42)	116(31.87)		25(14.71)	22(12.94)	
40~60	217(59.61)	212(58.24)		123(72.35)	122(71.76)	
≥60	29(7.97)	36(9.89)		22(12.94)	26(15.30)	
Educational level			0.04			0.75
primary school and less than	10(2.75)	23(6.32)		30(17.65)	26(15.29)	
junior middle and high school	147(40.38)	128(35.16)		76(44.70)	74(43.53)	
junior college or above	207(56.87)	213(58.52)		64(37.65)	70(41.18)	
Occupational status			0.39			0.43
mental labour	108(29.67)	104(28.57)		50(29.41)	48(28.24)	
physical labor	86(23.63)	102(28.02)		25(14.71)	34(20.00)	
other	170(46.70)	158(43.41)		95(55.88)	88(51.76)	
Income(yuan/month)			0.35			0.85
<2000	17(4.67)	17(4.67)		15(8.82)	18(10.59)	
2000~3000	87(23.90)	104(28.57)		70(41.18)	70(41.18)	
≥3000	260(71.43)	243(66.76)		85(50.00)	82(48.23)	
Marital status			0.24			0.52
single	45(12.36)	56(15.38)		4(2.35)	6(3.53)	
married or other	319(87.64)	308(84.62)		166(97.65)	164(96.47)	
Smoking status			0.30			0.16
never smoker	199(54.67)	213(58.52)		168(98.82)	170(100)	
smoker	165(45.33)	151(41.48)		2(1.18)	0(0.00)	
Tea-drinking status			0.30			0.01
yes	258(70.88)	245(63.31)		77(45.29)	55(32.35)	
no	106(29.12)	119(32.69)		93(54.71)	115(67.55)	
Physical activity			0.02			0.88
light	175(48.08)	137(37.64)		19(11.18)	19(11.18)	
moderate	100(27.47)	121(33.24)		47(27.64)	43(25.29)	
severe	89(24.45)	106(29.12)		104(61.18)	108(63.53)	
BMI(kg/m ²)			<0.001			<0.001
<18.5	2(0.55)	11(3.02)		1(0.59)	9(5.29)	
18.5~24.0	107(29.40)	257(70.61)		72(42.35)	125(73.53)	
≥24.0	255(70.05)	96(26.37)		97(57.06)	36(21.18)	
History of diabetes			0.67			0.18
yes	12(3.30)	10(2.75)		10(5.88)	5(2.94)	
no	352(96.70)	354(97.25)		160(94.12)	165(94.06)	
History of hypertension			0.85			0.63
yes	15(4.12)	16(4.40)		8(4.71)	10(5.88)	
no	349(95.88)	348(95.60)		162(95.29)	160(94.12)	
History of hyperlipidemia			0.01			<0.001
yes	108(29.67)	77(21.15)		51(30.00)	21(12.35)	
no	256(70.33)	287(78.85)		119(70.00)	149(87.65)	
MUFA intake, g/d ^b	34.10(28.49, 31.39)	26.55(26.55, 36.79)	<0.001	29.99(26.37, 36.37)	28.05(22.40, 31.39)	<0.001
PUFA intake, g/d ^b	26.25(24.04, 23.90)	22.01(26.02)	<0.001	24.52(22.11, 27.12)	21.21(18.83, 24.53)	<0.001
Energy intake, kJ/d ^c	10395.64±24989.07	97±2348.76	0.01	7509.73±1650.71	7323.78±1852.97	0.04

^aP-values were calculated by using the Chi-square test for categorical variables and Wilcoxon rank sum test and ANOVA test for continues variables.

^bMedians (IQRs).

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

^cMean(s.d).

The associations of dietary nut intake with NAFLD

The participants' nut consumption is summarized in Table 2. Among the women, those in the NAFLD group consumed a significantly higher amount of nuts (6.80 g/d vs. 2.50 g/d; $P = 0.02$) than those in the control group. No statistically significant differences were found between the cases and controls in the the sample or among the male participants. In order to adjust for potential confounding factors, quartile distributions of dietary nut consumption among the controls were used to categorize the nut intake of all the participants; the results are shown in Table 3. After adjusting for potential confounders, nut consumption was not associated with NAFLD risk among the participants in the sample. When the fully adjusted model was stratified by sex, a significant inverse association was found between nut consumption and NAFLD, but only among the men in the highest quartile (OR = 0.43; 95% CI: 0.26–0.71; $P_{\text{trend}} = 0.01$).

Table 2 Comparison of nut daily intake between the case and the control

Nut intake (g/d)	Case		Control		<i>P</i> -value ^a	<i>P</i> -value ^b
	Median	Quartile	Median	Quartile		
Total population	3.15	1.46-8.80	2.86	1.22-8.98	0.35	0.18
Men	2.68	1.15-8.43	2.86	1.22-8.98	0.36	0.94
Women	6.80	1.75-8.86	2.50	1.07-7.84	0.01	0.02

^a*P*-values:calculated by using Wilcoxon rank sum test;before adjusting for energy.

^b*P*-values :calculated by using Wilcoxon rank sum test; after adjusting for energy by using the residuals methods.

Table 3 Odds ratios (OR) and 95% confidence intervals (CI) for NAFLD in relation to nut intake

Nut intake	Case <i>n</i>	Control <i>n</i>	Crude OR(95%CI)	Model 1 ^a OR(95%CI)	Model 2 ^a OR(95%CI)
Total population ^b	534	534			
Q1	125	133	1	1	1
Q2	112	134	1.30(0.93-1.81)	0.89(0.63-1.26)	0.85(0.56-1.29)
Q3	159	134	1.77(1.29-2.44)	1.26(0.90-1.77)	1.01(0.68-1.50)
Q4	138	133	1.17(0.81-1.68)	1.10(0.78-1.55)	0.67(0.44-1.02)
<i>P</i> for trend*			0.46	0.45	0.07
Men	364	364			
Q1	106	102	1	1	1
Q2	91	79	1.31(0.88-1.94)	0.90(0.60-1.35)	0.88(0.54-1.43)
Q3	74	123	1.81(1.24-2.65)	1.73(1.16-2.57)	1.34(0.84-2.16)
Q4	93	60	1.04(0.66-1.63)	0.67(0.44-1.02)	0.43(0.26-0.71)
<i>P</i> for trend*			0.81	0.04	0.01
Women	170	170			
Q1	23	27	1	1	1
Q2	33	43	1.28(0.69-2.37)	0.90(0.44-1.85)	0.84(0.36-1.97)
Q3	36	60	1.71(0.95-3.08)	0.70(0.35-1.41)	0.55(0.24-1.25)
Q4	78	40	1.41(0.76-2.64)	2.29(1.17-4.49)	1.30(0.57-2.95)
<i>P</i> for trend*			0.36	<0.001	0.12

^aModel 1: Adjusted for total energy intake.

^aModel 2: Adjusted further for age, income, smoking status, educational level, teaing status, occupationanl status, marital status, body mass index, physical activity, the history of diabetes, hypertension and hyperlipidemia, MUFA and PUFA intake.

^b: further adiusted for sex.

**P* for trend: Trend across intake levels with the categorical median.

For total population: Q1, <1.46 g/d; Q2, 1.46-3.15 g/d; Q3, 3.15-8.80 g/d; Q4, ≥8.80 g/d

For men: Q1, <1.15 g/d; Q2, 1.15-2.68 g/d; Q3, 2.68-8.43 g/d; Q4, ≥8.43g/d

For women: Q1, <1.75 g/d; Q2, 1.75-6.80 g/d; Q3, 6.80-8.86 g/d; Q4, ≥8.86 g/d.

Stratified Analyses

In the stratified analysis, the inverse association between total-nut consumption and NAFLD risk was consistent across strata of age, sex, BMI, educational level, income, physical activity, smoking, tea drinking, and history of diabetes, hypertension, and hyperlipidemia. In addition to the association between nut consumption and

1
2
3 NAFLD in men, we also found the highest nut-consumption category was associated
4 with a lower risk of developing NAFLD than the reference (OR = 0.53; 95% CI:
5 0.31–0.93) among the participants who engaged in light and moderate physical
6 activity. No significant interactions of total nut consumption and the potentially
7 confounding effects of NAFLD risk factors were identified (Figure 1).
8
9
10
11
12
13

14 **Discussion**

15
16
17 In this case-control study, we found a significant inverse relationship between
18 high nut consumption and NAFLD risk among the males, but found either no or
19 unclear associations among the females and the overall sample. Moreover, the
20 associations seemed to be independent of other predictors, including diet and lifestyle
21 factors. The effect of nut consumption remained among men after controlling for
22 other known or suspected risk factors for developing NAFLD. Furthermore, no
23 significant interactions between nut consumption and the potential modifying effects
24 of NAFLD risk factors were identified. To the best of our knowledge, this was the
25 first study to assess the association between nut consumption and the risk of NAFLD
26 in a Chinese sample.
27
28
29
30
31
32
33
34
35
36
37
38
39

40 Our results are consistent with a previous study conducted in Korea, which found
41 that a low intake of nuts and seeds (OR = 3.66; $P_{\text{trend}} = 0.007$) was associated with a
42 significantly higher risk of developing NAFLD among male participants, but not
43 among females²⁴. Although another case-control study found an association between
44 a high intake of nuts with a lower likelihood of NAFLD, after adjusting for the
45 confounders age, sex, waist circumference, and the values of the homeostasis model
46 assessment of insulin resistance (OR = 0.61; 95% CI: 0.38–0.98), the association
47 disappeared after further adjustment for adiponectin and TNF- α (OR = 0.72; 95% CI:
48 0.41–1.25)¹⁸. However, the study did not examine nut intake separately; therefore,
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 the results cannot be directly compared with those of our study. Although the results
4
5 of our study suggest nuts may play a protective role in the development of NAFLD in
6
7 males, a significant association between nut intake and the risk of NAFLD was not
8
9 found in females. NAFLD has been regarded as the “hepatic manifestation of MetS”;
10
11 therefore, our findings are indirectly supported by several studies showing an inverse
12
13 correlation between high nut intake and the risk of T2D and cardiovascular disease,
14
15 which share common metabolic parameters with NAFLD ²⁵⁻²⁷. Nevertheless, the
16
17 relationship between nut intake and NAFLD warrants further exploration, and
18
19 additional studies are needed to examine gender differences in the association
20
21 between nut consumption and NAFLD, and its’ possible mechanisms should be
22
23 explored.
24
25
26
27

28
29 Several biological pathways have been proposed to explain the association
30
31 between nut intake and NAFLD risk. Ellagic acid, a natural antioxidant polyphenol
32
33 found in nuts, can suppress oxidative stress and inflammation ²⁸ and improve hepatic
34
35 insulin sensitivity and lipid metabolism ²⁹. Vitamin E and selenium in almonds and
36
37 walnuts, as well as folic acid and resveratrol in pine nuts, have been reported to have
38
39 beneficial effects on NAFLD. Numerous trials testing the therapeutic value of vitamin
40
41 E in NAFLD prevention found that Vitamin E significantly improved liver function
42
43 and histologic changes by significantly reducing aspartate aminotransferase, alanine
44
45 aminotransferase, steatosis, and inflammation in patients with NAFLD/non-alcoholic
46
47 steatohepatitis (NASH) ³⁰. Selenium is an antioxidant agent, and selenium deficiency
48
49 is associated with insulin resistance in patients with chronic liver disease ³¹. Folate
50
51 plays an essential role in lipid metabolism and folic acid supplementation can
52
53 attenuate steatosis and improve oxidative stress in rodent models of NAFLD. Folate
54
55 can also blunt the increase of inflammatory cytokines secreted by immune cells ³².
56
57
58
59
60

1
2
3 Resveratrol has antioxidant, anti-apoptotic, and anti-inflammatory properties in
4 NAFLD patients³³. Nuts, which are known to be rich in unsaturated fatty acids, are
5 especially rich in n-3 PUFAs, a source of alpha-linolenic acid, which lowers LDL
6 cholesterol³⁴, and has been found to have beneficial effects on NAFLD³⁵. Each type
7 of nut has many nutrients and phytochemicals that may be beneficial to health, and it
8 is likely that unknown salubrious effects of nuts may be related to NAFLD prevention.
9
10 Moreover, many studies have shown a beneficial association between high nut intake
11 and decreased risk of obesity³⁶, T2D³⁷, and MetS³⁸, which are risk factors for
12 NAFLD.
13
14

15
16
17 Our study has both strengths and limitations. The first strength is the large sample
18 size, which may have reduced type II errors. Second, the collection of data using
19 face-to-face interviews and a semi-quantitative food frequency questionnaire, which
20 elicited extensive information on anthropometrics and lifestyle factors, allowed us to
21 adjust for confounding factors. Finally, the study tried to investigate interactions
22 between nut intake and other risk factors, for which a biologically plausible
23 mechanism may exist. Nonetheless, several limitations should be considered when
24 interpreting the study's findings. First, although we accounted for a wide range of
25 socioeconomic characteristics and lifestyle factors, we cannot exclude the effects of
26 unknown or poorly measured confounding variables or residual confounding
27 attributable to other dietary/lifestyle factors, which might have influenced the
28 observed associations. However, the associations persisted even after controlling for
29 known and suspected predictors of NAFLD. Second, the intake of nuts was assessed
30 by asking about using one question; therefore, we could not investigate the effects of
31 different types of nuts, such as peanuts and walnuts, which contain different amounts
32 of energy, fat content, and other nutrients³⁹. Third, categorization of the intake of nuts
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 in quartiles may lead to bias and inefficiency. Fourth, we did not consider
4 manufacturing methods (e.g., raw, roasted, or boiled) or extra ingredients (e.g., sugar,
5 salt, seasoning). Different preparation methods before and after roasting, the amount
6 of time roasted, and the temperature used can affect the nutrient composition and
7 ingredients in the nuts^{40 41}. What's more, the item 'nuts' in the FFQ used in this study
8 cannot represent all nuts, because it only included peanuts, walnuts, seeds. For this
9 reason, direct comparisons with the results of other studies may be difficult. Fifth,
10 because we used a case-control study design, recall bias is an inherent limitation.
11 People who are health-conscious may over-report or under-report some food items.
12 However, the protective effect of nuts on NAFLD was not generally known at the
13 time of the survey, and thus, should be unrelated to recall bias. In addition, the
14 stratified analyses was not corrected for multiple testing, which may inflate the risk
15 for type I error. Sixth, NAFLD is a spectrum of disease ranging from essentially
16 benign simple steatosis (fatty infiltration of the liver) to the more severe form
17 non-alcoholic steatohepatitis (NASH- fat with inflammation and/or fibrosis), but we
18 did not collect data about the severity of NAFLD, so we can't analysis the
19 association between nuts intake with the the severity of NAFLD. Finally, due to the
20 small number of participants in the highest nut-intake category, we cannot rule out the
21 possibility that some of our results are due to chance. However, the associations were
22 consistent in the analyses stratified by some of the other factors, which reduces the
23 likelihood of chance findings. In these stratified analyses, the statistical power needed
24 to detect differences was limited by the sample size, and such analyses should be
25 considered exploratory.

26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56 Our study had a retrospective design, which is lower on the evidence hierarchy than
57 prospective studies. Nevertheless, case-control studies can provide evidence
58
59
60

1
2
3 supporting the general relationship between diet and NAFLD, as there currently are
4
5 no available prospective studies.
6
7

8 In conclusion, this case-control study indicated that high nut intake was associated
9
10 with a significantly reduced risk of NAFLD among Han men in China. However, no
11
12 relationship was found between total nut intake and NAFLD risk among the Han
13
14 women. Our data contribute to the growing evidence showing that a relatively simple
15
16 prevention strategy of incorporating a modest amount of nuts in the diet may
17
18 contribute to maintaining good health at both the individual and population levels.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

We thank all study participants for their cooperation. We also thank our staff for recruiting participants and for their technical assistance.

Contributors

BBC and YH are joint first authors. XEP obtained funding. XEP, XL and SHX designed the study. XTP, JHY, YFL and WJL collected the data. BBC and YH were involved in data cleaning and verification. BBC and XTP analyzed the data. BBC and YH drafted the manuscript. XEP, YFL and JHY contributed to the interpretation of the results and critical revision of the manuscript for important intellectual content and approved the final version of the manuscript. All authors have read and approved the final manuscript.

Data sharing

No additional data are available.

Conflict of Interest

The authors declare that they have no conflict of interest.

Funding

This work was supported by the National Natural Science Foundation of China [grant number 81473047], the Training Program Foundation for Middle-aged and Young Talents from the Sanitation System of Fujian Province [grant number 2014-ZQN-ZD-23], and the Joint Innovation Project of Science and Technology of Fujian Province [grant number 2017Y9104].

References

1. Maurice J, Manousou P. Non-alcoholic fatty liver disease. *Clin Med (Lond)* 2018;**18(3)**:245-50. doi: 10.7861/clinmedicine.18-3-245
2. Rietman A, Sluik D, Feskens E, *et al.* Associations between dietary factors and markers of NAFLD in a general Dutch adult population. *Eur J Clin Nutr* 2018;**72(1)**:117-23. doi: 10.1038/ejcn.2017.148
3. Fan J. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. *J Gastroenterol Hepatol* 2013;**28 Suppl 1**:11-17. doi: 10.1111/jgh.12036
4. Katsagoni C, Georgoulis M, Papatheodoridis G, *et al.* Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. *Metab Clin Exp* 2017;**68**:119-32. doi: 10.1016/j.metabol.2016.12.006
5. Zelber-Sagi S, Salomone F, Mlynarsky L. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanisms. *Liver Int* 2017;**37(7)**:936-49. doi: 10.1111/liv.13435
6. Kosmidou M, Milionis H. Diabetes mellitus and non-alcoholic fatty liver disease: the thread of Ariadne. *Minerva Endocrinol* 2017;**42(2)**:109-21. doi: 10.23736/S0391-1977.16.02562-1
7. Petrović G, Bjelaković G, Benedeto-Stojanov D, *et al.* Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound. *Vojnosanit Pregl* 2016;**73(10)**:910-20. doi: 10.2298/vsp150514093p
8. Ros E. Health benefits of nut consumption. *Nutrients* 2010;**2(7)**:652-82. doi: 10.3390/nu2070652
9. Lee J, Shin A, Oh JH, *et al.* The relationship between nut intake and risk of colorectal cancer: a case control study. *Nutr J* 2018;**17(1)**:37. doi: 10.1186/s12937-018-0345-y
10. Lahong J, Dongmei Y, Xiaoli X. Status and variation trend of nut intake among Chinese residents,2010-2012. *Chin J Public Health* 2017;**33(6)**:916-18.

- 1
2
3
4 11. Larsson S, Drca N, Björck M, *et al.* Nut consumption and incidence of seven
5 cardiovascular diseases. *Heart* 2018 doi: 10.1136/heartjnl-2017-312819
6
- 7
8 12. Asghari G, Ghorbani Z, Mirmiran P, *et al.* Nut consumption is associated with
9 lower incidence of type 2 diabetes: The Tehran Lipid and Glucose Study.
10
11 *Diabetes Metab* 2017;**43(1)**:18-24. doi: 10.1016/j.diabet.2016.09.008
12
- 13
14 13. O'Neil C, Fulgoni V, Nicklas T. Tree Nut consumption is associated with better
15 adiposity measures and cardiovascular and metabolic syndrome health risk
16 factors in U.S. Adults: NHANES 2005-2010. *Nutr J* 2015;**14**:64. doi:
17
18 10.1186/s12937-015-0052-x
19
- 20
21 14. Casas-Agustench P, López-Uriarte P, Bulló M, *et al.* Effects of one serving of
22 mixed nuts on serum lipids, insulin resistance and inflammatory markers in
23 patients with the metabolic syndrome. *Nutr Metab Cardiovasc Dis*
24
25 2011;**21(2)**:126-35. doi: 10.1016/j.numecd.2009.08.005
26
27
- 28
29 15. Hernández-Alonso P, Salas-Salvadó J, Baldrich-Mora M, *et al.* Beneficial effect
30 of pistachio consumption on glucose metabolism, insulin resistance,
31 inflammation, and related metabolic risk markers: a randomized clinical trial.
32
33 *Diabetes Care* 2014;**37(11)**:3098-105. doi: 10.2337/dc14-1431
34
35
- 36
37 16. Grosso G, Yang J, Marventano S, *et al.* Nut consumption on all-cause,
38 cardiovascular, and cancer mortality risk: a systematic review and
39 meta-analysis of epidemiologic studies. *Am J Clin Nutr* 2015;**101(4)**:783-93.
40
41 doi: 10.3945/ajcn.114.099515
42
43
- 44
45 17. Dreher M, Maher C, Kearney P. The traditional and emerging role of nuts in
46 healthful diets. *Nutr Rev* 1996;**54(8)**:241-45.
47
- 48
49 18. Katsagoni C, Georgoulis M, Papatheodoridis G, *et al.* Associations Between
50 Lifestyle Characteristics and the Presence of Nonalcoholic Fatty Liver
51 Disease: A Case-Control Study. *Metab Syndr Relat Disord* 2017;**15(2)**:72-79.
52
53 doi: 10.1089/met.2016.0105
54
55
- 56
57 19. L K, T T, S F, *et al.* Relative validity of a semi-quantitative food frequency
58 questionnaire versus 3 day weighed diet records in middle-aged inhabitants in
59 Chaoshan area, China. *Asian Pacific journal of cancer prevention : APJCP*
60

- 2005;**6(3)**:376-81.
20. MA M, NP J, S G. Case-control matching: effects, misconceptions, and recommendations. *European journal of epidemiology* 2018;**33(1)**:5-14. doi: 10.1007/s10654-017-0325-0
21. T F, S Z, D N, *et al.* Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2018;**36(11)**:1112-20. doi: 10.1200/JCO.2017.75.5413
22. MA F, K S, D N, *et al.* Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance). *PloS one* 2014;**9(6)**:e99816. doi: 10.1371/journal.pone.0099816
23. JA M, K S, D N, *et al.* Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. *Journal of the National Cancer Institute* 2012;**104(22)**:1702-11. doi: 10.1093/jnci/djs399
24. Han JM, Jo AN, Lee SM, *et al.* Associations between intakes of individual nutrients or whole food groups and non-alcoholic fatty liver disease among Korean adults. *Journal of Gastroenterology and Hepatology* 2014;**29(6)**:1265-72. doi: 10.1111/jgh.12520
25. Edens M, Kuipers F, Stolk R. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. *Obes Rev* 2009;**10(4)**:412-19. doi: 10.1111/j.1467-789X.2009.00594.x
26. Lonardo A, Ballestri S, Guaraldi G, *et al.* Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. *World J Gastroenterol* 2016;**22(44)**:9674-93. doi: 10.3748/wjg.v22.i44.9674
27. Gastaldelli A. Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD? *Clin Sci* 2017;**131(22)**:2701-04. doi: 10.1042/CS20170987
28. Panchal SK, Ward L, Brown L. Ellagic acid attenuates high-carbohydrate, high-fat

- 1
2
3 diet-induced metabolic syndrome in rats. *Eur J Nutr* 2013;**52(2)**:559-68. doi:
4 10.1007/s00394-012-0358-9
5
6
7
8 29. Polce S, Burke C, França L, *et al.* Ellagic Acid Alleviates Hepatic Oxidative
9 Stress and Insulin Resistance in Diabetic Female Rats. *Nutrients*
10 2018;**10(5)**:1-15. doi: 10.3390/nu10050531
11
12
13 30. Sato K, Gosho M, Yamamoto T, *et al.* Vitamin E has a beneficial effect on
14 nonalcoholic fatty liver disease: a meta-analysis of randomized controlled
15 trials. *Nutrition* 2015;**31(7-8)**:923-30. doi: 10.1016/j.nut.2014.11.018
16
17
18 31. Himoto T, Yoneyama H, Kurokohchi K, *et al.* Selenium deficiency is associated
19 with insulin resistance in patients with hepatitis C virus-related chronic liver
20 disease. *Nutr Res* 2011;**31(11)**:829-35. doi: 10.1016/j.nutres.2011.09.021
21
22
23 32. Sid V, Siow Y, O K. Role of folate in nonalcoholic fatty liver disease. *Can J*
24 *Physiol Pharmacol* 2017;**95(10)**:1141-48. doi: 10.1139/cjpp-2016-0681
25
26
27 33. Hajjighasem A, Farzanegi P, Mazaheri Z. Effects of combined therapy with
28 resveratrol, continuous and interval exercises on apoptosis, oxidative stress,
29 and inflammatory biomarkers in the liver of old rats with non-alcoholic fatty
30 liver disease. *Arch Physiol Biochem* 2018:1-8. doi:
31 0.1080/13813455.2018.1441872
32
33
34 34. Jeznach-Steinhagen A, Ostrowska J, Czerwonogrodzka-Senczyzna A, *et al.*
35 [Dietary recommendation for non-alcoholic fatty liver disease]. *Pol Merkur*
36 *Lekarski* 2017;**43(258)**:281-86.
37
38
39 35. Musa-Veloso K, Venditti C, Lee H, *et al.* Systematic review and meta-analysis of
40 controlled intervention studies on the effectiveness of long-chain omega-3
41 fatty acids in patients with nonalcoholic fatty liver disease. *Nutr Rev*
42 2018;**0(0)**:1-22. doi: 10.1093/nutrit/nuy022
43
44
45 36. Mohammadifard N, Yazdekhashti N, Stangl G, *et al.* Inverse association between
46 the frequency of nut consumption and obesity among Iranian population:
47 Isfahan Healthy Heart Program. *Eur J Nutr* 2015;**54(6)**:925-31. doi:
48 10.1007/s00394-014-0769-x
49
50
51 37. Hernández-Alonso P, Camacho-Barcia L, Bulló M, *et al.* Nuts and Dried Fruits:
52
53
54
55
56
57
58
59
60

- 1
2
3
4 An Update of Their Beneficial Effects on Type 2 Diabetes. *Nutrients*
5 2017;**9(7)**:673. doi: 10.3390/nu9070673
6
7
8 38. Hosseinpour-Niazi S, Hosseini S, Mirmiran P, *et al.* Prospective Study of Nut
9 Consumption and Incidence of Metabolic Syndrome: Tehran Lipid and
10 Glucose Study. *Nutrients* 2017;**9(10)**:1056. doi: 10.3390/nu9101056
11
12
13 39. Wu L, Wang Z, Zhu J, *et al.* Nut consumption and risk of cancer and type 2
14 diabetes: a systematic review and meta-analysis. *Nutr Rev* 2015;**73(7)**:409-25.
15 doi: 10.1093/nutrit/nuv006
16
17
18
19 40. Schlörmann W, Birringer M, Böhm V, *et al.* Influence of roasting conditions on
20 health-related compounds in different nuts. *Food Chem* 2015;**180**:77-85. doi:
21 10.1016/j.foodchem.2015.02.017
22
23
24
25 41. Hosseini Bai S, Darby I, Nevenimo T, *et al.* Effects of roasting on kernel peroxide
26 value, free fatty acid, fatty acid composition and crude protein content. *PLoS*
27 *ONE* 2017;**12(9)**:e0184279. doi: 10.1371/journal.pone.0184279
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

Figure 1. Odds ratios (OR) and 95% CIs for NAFLD across the strata of various factors.

The forest plot represents the ORs of the comparison of the lowest nut-intake category versus the highest nut-intake category, adjusting for age, income, smoking status, educational level, tea-drinking status, occupational status, marital status, BMI, physical activity, history of diabetes, hypertension and hyperlipidemia, total energy intake, and MUFA and PUFA intake. P -values are two-tailed; P_{inter} indicates P for the interaction between strata and nut intake; P_{trend} indicates P for the trend across levels of nut intake.




Figure 1. Odds ratios (OR) and 95% CIs for NAFLD across the strata of various factors. The forest plot represents the ORs of the comparison of the lowest nut-intake category versus the highest nut-intake category, adjusting for age, income, smoking status, educational level, tea-drinking status, occupational status, marital status, BMI, physical activity, history of diabetes, hypertension and hyperlipidemia, total energy intake, and MUFA and PUFA intake. P-values are two-tailed; Pinter indicates P for the interaction between strata and nut intake; Ptrend indicates P for the trend across levels of nut intake.

148x159mm (96 x 96 DPI)

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *case-control studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	5
		(b) For matched studies, give matching criteria and the number of controls per case	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-6
Bias	9	Describe any efforts to address potential sources of bias	7

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6-7
		(b) Describe any methods used to examine subgroups and interactions	7
		(c) Explain how missing data were addressed	
		(d) If applicable, explain how matching of cases and controls was addressed	5
		(e) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8-9
		(b) Indicate number of participants with missing data for each variable of interest	
Outcome data	15*	Report numbers in each exposure category, or summary measures of exposure	8-9
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-10
		(b) Report category boundaries when continuous variables were categorized	10-11

		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	11
Discussion			
Key results	18	Summarise key results with reference to study objectives	12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	15
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	17

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Association between nut intake and Non-alcoholic fatty liver disease risk: a retrospective case-control study in a sample of Chinese Han adults

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-028961.R3
Article Type:	Research
Date Submitted by the Author:	05-Aug-2019
Complete List of Authors:	Chen, Bing bing; Fujian Medical University, Han, Ying; The First Affiliated Hospital of Fujian Medical University Pan, Xinting; Department of Epidemiology and Health Statistics, Fujian Provincial Key Laboratory of Environment Factors and Cancer, School of Public Health, Fujian Medical University Yan, Jianhui; Department of Epidemiology and Health Statistics, Fujian Provincial Key Laboratory of Environment Factors and Cancer, School of Public Health, Fujian Medical University Liu, Wenjuan; Department of Epidemiology and Health Statistics, Fujian Provincial Key Laboratory of Environment Factors and Cancer, School of Public Health, Fujian Medical University li, yangfan; Department of Epidemiology and Health Statistics, Fujian Provincial Key Laboratory of Environment Factors and Cancer, School of Public Health, Fujian Medical University, Fujian, China, ; lin, xu; Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fujian, China xu, shanghua; Department of Cardiology, Affiliated Nanping First Hospital, Fujian Medical University, Nanping, China Peng, Xian-E; Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fujian,
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Nutrition and metabolism, Public health
Keywords:	EPIDEMIOLOGY, NUTRITION & DIETETICS, Lipid disorders < DIABETES & ENDOCRINOLOGY

SCHOLARONE™
Manuscripts

1
2
3
4 **Association between nut intake and Non-alcoholic fatty liver disease risk: a**
5 **retrospective case-control study in a sample of Chinese Han adults**
6

7 Bingbing Chen^{1#}, Ying Han^{2#}, Xinting Pan¹, Jianhui Yan¹, Wenjuan Liu¹, Yangfan Li¹, Xu Lin³,
8 Shanghua Xu⁴, Xian-e Peng^{1,3*}
9

10 ¹ Department of Epidemiology and Health Statistics, Fujian Provincial Key
11 Laboratory of Environment Factors and Cancer, School of Public Health, Fujian
12 Medical University, Fujian, China;
13
14

15
16
17 ² The First Affiliated Hospital of Fujian Medical University
18

19 ³ Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian
20 Medical University, Fujian, China;
21
22

23
24 ⁴ Department of Cardiology, Affiliated Nanping First Hospital, Fujian Medical
25 University, Nanping, China
26
27

28 [#] Both authors contributed equally to this work.
29

30 ^{*} Corresponding author. Xian-E Peng, Department of Epidemiology and Health
31 Statistics, Fujian Provincial Key Laboratory of Environment Factors and Cancer,
32 School of Public Health, Fujian Medical University, Fujian, China, 3501018
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Phone: +86-0591 22862648; E-mail: fmuxe@163.com

Running title: Nut intake and non-alcoholic fatty liver disease

Word count: 3055

Abstract

Objectives: Nut consumption has been associated with a lower risk of type 2 diabetes, metabolic syndrome, and insulin resistance. However, its effect on the risk of non-alcoholic fatty liver disease (NAFLD) is unknown. Therefore, we investigated the relationship between nut consumption and NAFLD risk.

Setting and participants: We conducted a retrospective case-control study including 534 patients diagnosed with NAFLD and 534 controls matched by sex and age (± 5) from the Affiliated Nanping First Hospital of Fujian Medical University in China.

Main outcome measures: Information on dietary intake was collected using a semi-quantitative food frequency questionnaires and nut consumption was calculated. Nut consumption was categorized using quartiles based on the distribution of daily nut intake of the controls. Binary logistic regression models were used to estimate odds ratio (ORs) and the 95% confidence intervals (CIs) for the association between nut consumption and NAFLD risk.

Results: After adjusting for potential confounding variables, nut consumption was not associated with NAFLD risk in the overall sample. When the fully adjusted model was stratified by sex, a significant inverse association was found between high nut consumption and NAFLD only among the men in the highest quartile (OR = 0.43; 95% CI: 0.26–0.71; $P_{\text{trend}} = 0.01$). The inverse association of nut consumption with NAFLD risk in men remained significant after controlling for other known or suspected risk factors for NAFLD.

Conclusions: Diets with a higher intake of nuts may be associated with a decreased risk of NAFLD, particularly in men.

Strengths and limitations of this study

1. In this study, several potential confounding variables such as energy intake and physical activity, were taken into account.

2. The study had tried to investigate interactions between nut intake and other risk factors, for which a biologically plausible mechanism may exist.

3. This study was a case-control design, thus the causal association between nut intake and NAFLD could not be precisely identified.

4. This study was a case-control study, recall bias was inevitable and randomized controlled trial studies are therefore required for more accurate results.

Introduction

Non-alcoholic fatty liver disease (NAFLD) is defined as macrovesicular steatosis in $\geq 5\%$ of hepatocytes, in the absence of a secondary cause, such as alcohol or drug use. NAFLD has become a leading cause of chronic liver disease, with a 25% prevalence worldwide¹. Furthermore, a fatty liver is more prevalent in men compared with women². The prevalence of NAFLD among the adults in China's general population is approximately 15% (6.3–27.0%), depending on the population studied³. Many studies suggest that diet and lifestyle may significantly influence the risk of NAFLD^{4,5}. These studies indicate that type 2 diabetes (T2D)⁶, metabolic syndrome (MetS), obesity⁷, physical activity, and a high-fat diet⁴ are associated with an increased risk for the development of NAFLD.

Nuts are nutrient-dense foods with complex matrices rich in unsaturated fatty and other bioactive compounds (e.g., high-quality vegetable protein, fiber, minerals, tocopherols, phytosterols, and phenolic compounds)⁸. The global intake of nuts has increased by 59% over the past decade⁹. China's per capita intake of nuts was 2.2 g/day in 1982, and increased to 3.8g/day in 2012¹⁰. Although they are high in fat and

1
2
3 energy dense, a high intake of nuts has been associated with several health benefits,
4 including reduced risk of cardiovascular disease ¹¹, T2D ¹², MetS¹³, and insulin
5 resistance¹⁴ ¹⁵. Moreover, nuts have antioxidative effects by decreasing lipid
6 peroxidation and protecting against oxidative DNA damage ¹⁶. Beneficial health
7 effects have been attributed to the macronutrient and micronutrient profiles of nuts ¹⁷.

14 NAFLD is regarded as the “hepatic manifestation of MetS.” Few studies have
15 assessed the effects of nut intake on NAFLD, despite previous findings of an inverse
16 correlation between high nut consumption and the risk of T2D and cardiovascular
17 disease. In this study, we analyzed the association between nut intake and NAFLD
18 risk and the interactions between nut intake and other established NAFLD risk factors
19 in a large case-control study with a sample of Han adults in China.

28 **Methods**

30 **Patient and public involvement statement**

31 Patients and public will not be involved in the development of the research question
32 or in the design of the study. Subjects will receive oral and written information about
33 this study, however, they will not be involved in the recruitment and conduct of the
34 study. After signing an informed consent by the participants, they will be assessed for
35 eligibility and data collection will begin. Eligible subjects will be interviewed
36 face-to-face by investigators to collect data. In addition, all methods were performed
37 in accordance with the relevant guidelines and regulations.

52 **Study design**

53 We conducted the retrospective case-control study in a health examination
54 center at the Affiliated Nanping First Hospital of Fujian Medical University fro
55 m April 2015 to August 2017. Data were obtained from subjects who underwe
56
57
58
59
60

nt routine health examination in the examination center. Patients newly diagnosed with NAFLD using abdominal ultrasonography in accordance with the “Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010” were included in the study. Hepatic ultrasonography examination was performed by trained ultrasonographers who were blinded to the clinical and laboratory data. Hepatic steatosis was diagnosed by characteristic echo patterns according to conventional criteria, such as the evidence of diffuse hyper-echogenicity of the liver relative to the kidneys, ultrasound beam attenuation, and poor visualization of intrahepatic structures.

Sample size calculation

This study is a case-control design, thus we estimate the sample size based on the case-control study formula: $n = 2\bar{p}\bar{q}(z_{\alpha} + z_{\beta})^2 / (p_1 - p_0)^2$, $p_1 = \frac{p_0 RR}{1 + p_0(RR-1)}$, $\bar{p} = 0.5 \times (p_1 + p_0)$, $\bar{q} = 1 - \bar{p}$. By consulting the literature¹⁸, we estimate $OR_{\text{nut intake}} = 0.72$, $p_0 = 0.50$, $\alpha = 0.05$, $\beta = 0.20$, the calculated sample size was $N_{\text{case}} = N_{\text{control}} = 609$. Finally 1068 subjects (534 cases and 534 controls) were recruited in this study.

Outcome--eligibility of NAFLD cases and controls

All participants were of Chinese Han ethnicity. The cases were newly diagnosed with NAFLD. The exclusion criteria were as follows: (a) daily alcohol intake of >40 g (men) and >20 g (women), (b) a history of other liver diseases including drug-induced liver disease, viral hepatitis, autoimmune hepatitis, total parenteral nutrition, and hepatocellular degeneration, (c) taking hypolipidemic or weight reduction drugs, (d) age <18 or >70 years, (e) non-resident of Nanping, or (f) not of Han ethnicity. Adults who reported extremely abnormal levels of energy intake (2 511.60 kJ [600 kcal] or 17 581.20 kJ [4 200 kcal] per day for men; 2 093 kJ [500 kcal] or 14,651.00 kJ [3500

1
2
3 kcal] per day for women), and those who did not answer 25 or more food-related
4 items or questions about nut intake on the questionnaire, were excluded from the
5 study.
6
7
8
9

10 The controls were randomly selected from the same center during the study period.
11 Their eligibility criteria were identical to those of the cases, except for the
12 requirement of a diagnosis of liver steatosis; they were frequency-matched with cases
13 by age (within 5-yr intervals), gender, ethnicity, and region of origin.
14
15
16
17
18

19 **Ethical considerations**

20
21 All subjects who participated in this study provided written informed
22 consent and the study was approved by the local ethics committees of
23 Fujian Medical University (ethics number 2014096). In addition, all methods
24 were performed in accordance with the relevant guidelines and
25 regulations of the University.
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 **Potential confounders--Data measurements and data collection**

41 Trained interviewers performed a comprehensive medical history on each
42 participant that included eliciting information about their demographic and
43 socio-economic characteristics (e.g., age, gender, education, income, marriage status
44 and history of diabetes, hypertension, hyperlipidemiaand), lifestyle habits (e.g.,
45 smoking, drinking (alcohol), tea drinking, and physical activity), anthropometric
46 assessment (e.g., height, body weight and blood pressure). The data were obtained
47 from participants using structured questionnaires during face-to-face interviews.
48
49
50
51
52
53
54
55
56
57

58 **Exposure-Nut consumption**

1
2
3 Information about participants' typical food consumption was collected using a
4 semi-quantitative food frequency questionnaire that included 110 food items, which
5 was developed and validated in a sample from southern China ¹⁹. Participants were
6 asked to estimate the average frequency of consumption of selected foods using the
7 following response options: rarely, <once/month, 1–3 times/month, 1–2 times/week,
8 3–4 times/week, 5–6 times/week, once/day, twice/day, and >twice/day. Nut intake
9 was defined as the consumption of “peanuts, walnuts, seeds, or other nuts.” Data from
10 a semi-quantitative food frequency questionnaire were used to calculate daily nut and
11 energy intake. Nut consumption was converted to grams/day by multiplying the
12 food-intake frequency by fixed portion sizes. Nutrient intake, such as
13 mono-unsaturated fatty acids (MUFAs) and poly-unsaturated fatty acids (PUFAs)
14 were calculated by multiplying the intake frequency of each food by the nutrient
15 content of the specified portion, and summing the products of all the food items.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 **Statistical analyses**

34
35 Participants' characteristics were analyzed using Pearson's Chi-square test for
36 categorical variables, and Wilcoxon's rank-sum test and ANOVA for continuous
37 variables. Nut consumption was categorized by quartiles based on the distribution of
38 daily nut intake by the controls (Q1-Q4). Binary logistic regression models were used
39 to estimate the odds ratios (ORs) and their 95% confidence intervals (CIs) for the
40 associations between nut consumption and NAFLD risk. To account for the energy
41 content of the nut, our initial model adjusted for total energy intake by using the
42 residuals method. The final model adjusted for potential confounders, including age,
43 income, smoking status, educational level, and tea-drinking status, occupational status,
44 marital status, body mass index (BMI), physical activity, and history of diabetes,
45 hypertension, and hyperlipidemia. In order to reflect the matching protocol, when
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 adjust for age, we entered a term for residual age into the regression analysis²⁰. The
4
5 final model also adjusted for MUFA and PUFA intake to control for their effects. The
6
7 selection of covariates for the final model was based on clinical significance, results
8
9 of previous studies. We tested for linear trends across categories of nut intake by
10
11 assigning each participant the median value for each category and modeling this value
12
13 as a continuous variable, consistent with prior studies²¹⁻²³.
14
15

16
17 We evaluated the influence of nut consumption across strata of other potential
18
19 confounders, comparing participants in the highest nut-consumption category to the
20
21 lowest nut-consumption category(reference). We also analyzed the interactions of nut
22
23 consumption with age, sex, BMI, smoking status, educational level, tea-drinking
24
25 status, and other factors. We used the medians of the continuous variables to
26
27 categorize them and evaluate the interactions. The criteria for statistical significance
28
29 of the likelihood-ratio test of interaction effects was $P < 0.05$. Statistical analyses
30
31 were performed using SPSS version 22 (IBM, Armonk, NY, US). All P-values were
32
33 2-tailed, and $P < 0.05$ was considered statistically significant.
34
35
36

37 **Results**

38 **Baseline Characteristics**

39
40
41 Table 1 presents health-related and demographic characteristics of the NAFLD
42
43 cases and matched controls. Compared with the controls, the NAFLD cases tended to
44
45 have a higher BMI, higher total intake of energy, higher MUFA and PUFA
46
47 consumption, and a higher number of participants with a history of hyperlipidemia
48
49 among both men and women. Patients with NAFLD had a lower educational level and
50
51 the men engaged in less physical activity than the controls. No statistically significant
52
53 associations were found for age, occupational status, income, marital status, smoking
54
55 status, history of diabetes, or hypertension between the cases and the controls.
56
57
58
59
60

Table 1 General characteristics of cases and controls stratified by sex, n(%)

Variables	Men (n=728)			Women(n=340)		
	Cases (n=364)	Controls(n=364)	P-value ^a	Cases (n=170)	Controls(n=170)	P-value ^a
Age			0.66			0.99
<40	118(32.42)	116(31.87)		25(14.71)	22(12.94)	
40~60	217(59.61)	212(58.24)		123(72.35)	122(71.76)	
≥60	29(7.97)	36(9.89)		22(12.94)	26(15.30)	
Educational level			0.04			0.75
primary school and less than	10(2.75)	23(6.32)		30(17.65)	26(15.29)	
junior middle and high school	147(40.38)	128(35.16)		76(44.70)	74(43.53)	
junior college or above	207(56.87)	213(58.52)		64(37.65)	70(41.18)	
Occupational status			0.39			0.43
mental labour	108(29.67)	104(28.57)		50(29.41)	48(28.24)	
physical labor	86(23.63)	102(28.02)		25(14.71)	34(20.00)	
other	170(46.70)	158(43.41)		95(55.88)	88(51.76)	
Income(yuan/month)			0.35			0.85
<2000	17(4.67)	17(4.67)		15(8.82)	18(10.59)	
2000~3000	87(23.90)	104(28.57)		70(41.18)	70(41.18)	
≥3000	260(71.43)	243(66.76)		85(50.00)	82(48.23)	
Marital status			0.24			0.52
single	45(12.36)	56(15.38)		4(2.35)	6(3.53)	
married or other	319(87.64)	308(84.62)		166(97.65)	164(96.47)	
Smoking status			0.30			0.16
never smoker	199(54.67)	213(58.52)		168(98.82)	170(100)	
smoker	165(45.33)	151(41.48)		2(1.18)	0(0.00)	
Tea-drinking status			0.30			0.01
yes	258(70.88)	245(63.31)		77(45.29)	55(32.35)	
no	106(29.12)	119(32.69)		93(54.71)	115(67.55)	
Physical activity			0.02			0.88
light	175(48.08)	137(37.64)		19(11.18)	19(11.18)	
moderate	100(27.47)	121(33.24)		47(27.64)	43(25.29)	
severe	89(24.45)	106(29.12)		104(61.18)	108(63.53)	
BMI(kg/m ²)			<0.001			<0.001
<18.5	2(0.55)	11(3.02)		1(0.59)	9(5.29)	
18.5~24.0	107(29.40)	257(70.61)		72(42.35)	125(73.53)	
≥24.0	255(70.05)	96(26.37)		97(57.06)	36(21.18)	
History of diabetes			0.67			0.18
yes	12(3.30)	10(2.75)		10(5.88)	5(2.94)	
no	352(96.70)	354(97.25)		160(94.12)	165(94.06)	
History of hypertension			0.85			0.63
yes	15(4.12)	16(4.40)		8(4.71)	10(5.88)	
no	349(95.88)	348(95.60)		162(95.29)	160(94.12)	
History of hyperlipidemia			0.01			<0.001
yes	108(29.67)	77(21.15)		51(30.00)	21(12.35)	
no	256(70.33)	287(78.85)		119(70.00)	149(87.65)	
MUFA intake,g/d ^b	34.10(28.49,39	31.39(26.55,36.	<0.001	29.99(26.37,36.37)	28.05(22.40,31.39)	<0.001
PUFA intake,g/d ^b	26.25(24.04,29	23.90(22.01,26.	<0.001	24.52(22.11,27.12)	21.21(18.83,24.53)	<0.001
Energy intake,kJ/d ^c	10395.64±242	9890.97±2348.7	0.01	7509.73±1650.71	7323.78±1852.97	0.04

^aP-values were calculated by using the Chi-square test for categorical variables and Wilcoxon rank sum test and ANOVA test for continues variables.

^bMedians (IQRs).

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

^cMean(s.d).

The associations of dietary nut intake with NAFLD

The participants' nut consumption is summarized in Table 2. Among the women, those in the NAFLD group consumed a significantly higher amount of nuts (6.80 g/d vs. 2.50 g/d; $P = 0.02$) than those in the control group. No statistically significant differences were found between the cases and controls in the the sample or among the male participants. In order to adjust for potential confounding factors, quartile distributions of dietary nut consumption among the controls were used to categorize the nut intake of all the participants; the results are shown in Table 3. After adjusting for potential confounders, nut consumption was not associated with NAFLD risk among the participants in the sample. When the fully adjusted model was stratified by sex, a significant inverse association was found between nut consumption and NAFLD, but only among the men in the highest quartile (OR = 0.43; 95% CI: 0.26–0.71; $P_{\text{trend}} = 0.01$).

Table 2 Comparison of nut daily intake between the case and the control

Nut intake (g/d)	Case		Control		P -value ^a	P -value ^b
	Median	Quartile	Median	Quartile		
Total population	3.15	1.46-8.80	2.86	1.22-8.98	0.35	0.18
Men	2.68	1.15-8.43	2.86	1.22-8.98	0.36	0.94
Women	6.80	1.75-8.86	2.50	1.07-7.84	0.01	0.02

^a P -values:calculated by using Wilcoxon rank sum test;before adjusting for energy.

^b P -values :calculated by using Wilcoxon rank sum test; after adjusting for energy by using the residuals methods.

Table 3 Odds ratios (OR) and 95% confidence intervals (CI) for NAFLD in relation to nut intake

Nut intake	Case <i>n</i>	Control <i>n</i>	Crude OR(95%CI)	Model 1 ^a OR(95%CI)	Model 2 ^a OR(95%CI)
Total population ^b	534	534			
Q1	125	133	1	1	1
Q2	112	134	1.30(0.93-1.81)	0.89(0.63-1.26)	0.85(0.56-1.29)
Q3	159	134	1.77(1.29-2.44)	1.26(0.90-1.77)	1.01(0.68-1.50)
Q4	138	133	1.17(0.81-1.68)	1.10(0.78-1.55)	0.67(0.44-1.02)
<i>P</i> for trend*			0.46	0.45	0.07
Men	364	364			
Q1	106	102	1	1	1
Q2	91	79	1.31(0.88-1.94)	0.90(0.60-1.35)	0.88(0.54-1.43)
Q3	74	123	1.81(1.24-2.65)	1.73(1.16-2.57)	1.34(0.84-2.16)
Q4	93	60	1.04(0.66-1.63)	0.67(0.44-1.02)	0.43(0.26-0.71)
<i>P</i> for trend*			0.81	0.04	0.01
Women	170	170			
Q1	23	27	1	1	1
Q2	33	43	1.28(0.69-2.37)	0.90(0.44-1.85)	0.84(0.36-1.97)
Q3	36	60	1.71(0.95-3.08)	0.70(0.35-1.41)	0.55(0.24-1.25)
Q4	78	40	1.41(0.76-2.64)	2.29(1.17-4.49)	1.30(0.57-2.95)
<i>P</i> for trend*			0.36	<0.001	0.12

^aModel 1: Adjusted for total energy intake.

^aModel 2: Adjusted further for age, income, smoking status, educational level, teaing status, occupationanl status, marital status, body mass index, physical activity, the history of diabetes, hypertension and hyperlipidemia, MUFA and PUFA intake.

^b: further adiusted for sex.

**P* for trend: Trend across intake levels with the categorical median.

For total population: Q1, <1.46 g/d; Q2, 1.46-3.15 g/d; Q3, 3.15-8.80 g/d; Q4, ≥8.80 g/d

For men: Q1, <1.15 g/d; Q2, 1.15-2.68 g/d; Q3, 2.68-8.43 g/d; Q4, ≥8.43g/d

For women: Q1, <1.75 g/d; Q2, 1.75-6.80 g/d; Q3, 6.80-8.86 g/d; Q4, ≥8.86 g/d.

Stratified Analyses

In the stratified analysis, the inverse association between total-nut consumption and NAFLD risk was consistent across strata of age, sex, BMI, educational level, income, physical activity, smoking, tea drinking, and history of diabetes, hypertension, and hyperlipidemia. In addition to the association between nut consumption and

1
2
3 NAFLD in men, we also found the highest nut-consumption category was associated
4 with a lower risk of developing NAFLD than the reference (OR = 0.53; 95% CI:
5 0.31–0.93) among the participants who engaged in light and moderate physical
6 activity. No significant interactions of total nut consumption and the potentially
7 confounding effects of NAFLD risk factors were identified (Figure 1).
8
9
10
11
12
13

14 **Discussion**

15
16
17 In this case-control study, we found a significant inverse relationship between
18 high nut consumption and NAFLD risk among the males, but found either no or
19 unclear associations among the females and the overall sample. Moreover, the
20 associations seemed to be independent of other predictors, including diet and lifestyle
21 factors. The effect of nut consumption remained among men after controlling for
22 other known or suspected risk factors for developing NAFLD. Furthermore, no
23 significant interactions between nut consumption and the potential modifying effects
24 of NAFLD risk factors were identified. To the best of our knowledge, this was the
25 first study to assess the association between nut consumption and the risk of NAFLD
26 in a Chinese sample.
27
28
29
30
31
32
33
34
35
36
37
38
39

40 Our results are consistent with a previous study conducted in Korea, which found
41 that a low intake of nuts and seeds (OR = 3.66; $P_{\text{trend}} = 0.007$) was associated with a
42 significantly higher risk of developing NAFLD among male participants, but not
43 among females²⁴. Although another case-control study found an association between
44 a high intake of nuts with a lower likelihood of NAFLD, after adjusting for the
45 confounders age, sex, waist circumference, and the values of the homeostasis model
46 assessment of insulin resistance (OR = 0.61; 95% CI: 0.38–0.98), the association
47 disappeared after further adjustment for adiponectin and TNF- α (OR = 0.72; 95% CI:
48 0.41–1.25)¹⁸. However, the study did not examine nut intake separately; therefore,
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 the results cannot be directly compared with those of our study. Although the results
4
5 of our study suggest nuts may play a protective role in the development of NAFLD in
6
7 males, a significant association between nut intake and the risk of NAFLD was not
8
9 found in females. NAFLD has been regarded as the “hepatic manifestation of MetS”;
10
11 therefore, our findings are indirectly supported by several studies showing an inverse
12
13 correlation between high nut intake and the risk of T2D and cardiovascular disease,
14
15 which share common metabolic parameters with NAFLD ²⁵⁻²⁷. Nevertheless, the
16
17 relationship between nut intake and NAFLD warrants further exploration, and
18
19 additional studies are needed to examine gender differences in the association
20
21 between nut consumption and NAFLD, and its’ possible mechanisms should be
22
23 explored.
24
25
26
27

28
29 Several biological pathways have been proposed to explain the association
30
31 between nut intake and NAFLD risk. Ellagic acid, a natural antioxidant polyphenol
32
33 found in nuts, can suppress oxidative stress and inflammation ²⁸ and improve hepatic
34
35 insulin sensitivity and lipid metabolism ²⁹. Vitamin E and selenium in almonds and
36
37 walnuts, as well as folic acid and resveratrol in pine nuts, have been reported to have
38
39 beneficial effects on NAFLD. Numerous trials testing the therapeutic value of vitamin
40
41 E in NAFLD prevention found that Vitamin E significantly improved liver function
42
43 and histologic changes by significantly reducing aspartate aminotransferase, alanine
44
45 aminotransferase, steatosis, and inflammation in patients with NAFLD/non-alcoholic
46
47 steatohepatitis (NASH) ³⁰. Selenium is an antioxidant agent, and selenium deficiency
48
49 is associated with insulin resistance in patients with chronic liver disease ³¹. Folate
50
51 plays an essential role in lipid metabolism and folic acid supplementation can
52
53 attenuate steatosis and improve oxidative stress in rodent models of NAFLD. Folate
54
55 can also blunt the increase of inflammatory cytokines secreted by immune cells ³².
56
57
58
59
60

1
2
3 Resveratrol has antioxidant, anti-apoptotic, and anti-inflammatory properties in
4 NAFLD patients ³³. Nuts, which are known to be rich in unsaturated fatty acids, are
5 especially rich in n-3 PUFAs, a source of alpha-linolenic acid, which lowers LDL
6 cholesterol ³⁴, and has been found to have beneficial effects on NAFLD ³⁵. Each type
7 of nut has many nutrients and phytochemicals that may be beneficial to health, and it
8 is likely that unknown salubrious effects of nuts may be related to NAFLD prevention.
9
10 Moreover, many studies have shown a beneficial association between high nut intake
11 and decreased risk of obesity ³⁶, T2D ³⁷, and MetS ³⁸, which are risk factors for
12 NAFLD.
13
14

15
16
17 Our study has both strengths and limitations. The first strength is the large sample size,
18 which may have reduced type II errors. Second, the collection of data using
19 face-to-face interviews and a semi-quantitative food frequency questionnaire, which
20 elicited extensive information on anthropometrics and lifestyle factors, allowed us to
21 adjust for confounding factors. Finally, the study tried to investigate interactions
22 between nut intake and other risk factors, for which a biologically plausible
23 mechanism may exist. Nonetheless, several limitations should be considered when
24 interpreting the study's findings. First, although we accounted for a wide range of
25 socioeconomic characteristics and lifestyle factors, we cannot exclude the effects of
26 unknown or poorly measured confounding variables or residual confounding
27 attributable to other dietary/lifestyle factors, which might have influenced the
28 observed associations. However, the associations persisted even after controlling for
29 known and suspected predictors of NAFLD. Second, the intake of nuts was assessed
30 by asking about using one question; therefore, we could not investigate the effects of
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 different types of nuts, such as peanuts and walnuts, which contain different amounts
5
6 of energy, fat content, and other nutrients³⁹. Third, categorization of the intake of nuts
7
8 in quartiles may lead to bias and inefficiency. Fourth, we did not consider
9
10 manufacturing methods (e.g., raw, roasted, or boiled) or extra ingredients (e.g., sugar,
11
12 salt, seasoning). Different preparation methods before and after roasting, the amount
13
14 of time roasted, and the temperature used can affect the nutrient composition and
15
16 ingredients in the nuts^{40 41}. What's more, the item 'nuts' in the FFQ used in this study
17
18 cannot represent all nuts, because it only included peanuts, walnuts, seeds. For this
19
20 reason, direct comparisons with the results of other studies may be difficult. Fifth,
21
22 because we used a case-control study design, recall bias is an inherent limitation.
23
24 People who are health-conscious may over-report or under-report some food items.
25
26 However, the protective effect of nuts on NAFLD was not generally known at the
27
28 time of the survey, and thus, should be unrelated to recall bias. In addition, the
29
30 stratified analyses was not corrected for multiple testing, which may inflate the risk
31
32 for type I error. Sixth, NAFLD is a spectrum of disease ranging from essentially
33
34 benign simple steatosis (fatty infiltration of the liver) to the more severe form
35
36 non-alcoholic steatohepatitis (NASH- fat with inflammation and/or fibrosis). In the
37
38 present study, the data about the severity of NAFLD was absent, therefore we did not
39
40 analysis the association between nuts intake and the the severity of NAFLD. Seventh,
41
42 lack of interactions association between nut intake and other risk factors may be due
43
44 to lack of power, and a small interactive effect on NAFLD cannot be ruled out.
45
46 Finally, due to the small number of participants in the highest nut-intake category, we
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 cannot rule out the possibility that some of our results are due to chance. However,
5
6 the associations were consistent in the analyses stratified by some of the other factors,
7
8 which reduces the likelihood of chance findings. In these stratified analyses, the
9
10 statistical power needed to detect differences was limited by the sample size, and such
11
12 analyses should be considered exploratory.
13
14
15

16 Our study had a retrospective design, which is lower on the evidence hierarchy than
17
18 prospective studies. Nevertheless, case-control studies can provide evidence
19
20 supporting the general relationship between diet and NAFLD, as there currently are
21
22 no available prospective studies.
23
24

25 In conclusion, this case-control study indicated that high nut intake was associated
26
27 with a significantly reduced risk of NAFLD among Han men in China. However, no
28
29 relationship was found between total nut intake and NAFLD risk among the Han
30
31 women. Our data contribute to the growing evidence showing that a relatively simple
32
33 prevention strategy of incorporating a modest amount of nuts in the diet may
34
35 contribute to maintaining good health at both the individual and population levels.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

We thank all study participants for their cooperation. We also thank our staff for recruiting participants and for their technical assistance.

Contributors

BBC and YH are joint first authors. XEP obtained funding. XEP, XL and SHX designed the study. XTP, JHY, YFL and WJL collected the data. BBC and YH were involved in data cleaning and verification. BBC and XTP analyzed the data. BBC and YH drafted the manuscript. XEP, YFL and JHY contributed to the interpretation of the results and critical revision of the manuscript for important intellectual content and approved the final version of the manuscript. All authors have read and approved the final manuscript.

Data sharing

Extra data can be accessed via the Dryad data repository at <http://datadryad.org/> with the doi:10.5061/dryad.8nn2j46

Conflict of Interest

The authors declare that they have no conflict of interest.

Funding

This work was supported by the National Natural Science Foundation of China [grant number 81473047], the National Natural Science Foundation of Fujian Province [grant number 2019J01316], and the Joint Innovation Project of Science and Technology of Fujian Province [grant number 2017Y9104].

References

1. Maurice J, Manousou P. Non-alcoholic fatty liver disease. *Clin Med (Lond)* 2018;**18(3)**:245-50. doi: 10.7861/clinmedicine.18-3-245
2. Rietman A, Sluik D, Feskens E, *et al.* Associations between dietary factors and markers of NAFLD in a general Dutch adult population. *Eur J Clin Nutr* 2018;**72(1)**:117-23. doi: 10.1038/ejcn.2017.148
3. Fan J. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. *J Gastroenterol Hepatol* 2013;**28 Suppl 1**:11-17. doi: 10.1111/jgh.12036
4. Katsagoni C, Georgoulis M, Papatheodoridis G, *et al.* Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. *Metab Clin Exp* 2017;**68**:119-32. doi: 10.1016/j.metabol.2016.12.006
5. Zelber-Sagi S, Salomone F, Mlynarsky L. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanisms. *Liver Int* 2017;**37(7)**:936-49. doi: 10.1111/liv.13435
6. Kosmidou M, Milionis H. Diabetes mellitus and non-alcoholic fatty liver disease: the thread of Ariadne. *Minerva Endocrinol* 2017;**42(2)**:109-21. doi: 10.23736/S0391-1977.16.02562-1
7. Petrović G, Bjelaković G, Benedeto-Stojanov D, *et al.* Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound. *Vojnosanit Pregl* 2016;**73(10)**:910-20. doi: 10.2298/vsp150514093p
8. Ros E. Health benefits of nut consumption. *Nutrients* 2010;**2(7)**:652-82. doi: 10.3390/nu2070652
9. Lee J, Shin A, Oh JH, *et al.* The relationship between nut intake and risk of colorectal cancer: a case control study. *Nutr J* 2018;**17(1)**:37. doi: 10.1186/s12937-018-0345-y
10. Lahong J, Dongmei Y, Xiaoli X. Status and variation trend of nut intake among Chinese residents,2010-2012. *Chin J Public Health* 2017;**33(6)**:916-18.

- 1
2
3
4 11. Larsson S, Drca N, Björck M, *et al.* Nut consumption and incidence of seven
5
6 cardiovascular diseases. *Heart* 2018 doi: 10.1136/heartjnl-2017-312819
- 7
8 12. Asghari G, Ghorbani Z, Mirmiran P, *et al.* Nut consumption is associated with
9
10 lower incidence of type 2 diabetes: The Tehran Lipid and Glucose Study.
11
12 *Diabetes Metab* 2017;**43(1)**:18-24. doi: 10.1016/j.diabet.2016.09.008
- 13
14 13. O'Neil C, Fulgoni V, Nicklas T. Tree Nut consumption is associated with better
15
16 adiposity measures and cardiovascular and metabolic syndrome health risk
17
18 factors in U.S. Adults: NHANES 2005-2010. *Nutr J* 2015;**14**:64. doi:
19
20 10.1186/s12937-015-0052-x
- 21
22 14. Casas-Agustench P, López-Uriarte P, Bulló M, *et al.* Effects of one serving of
23
24 mixed nuts on serum lipids, insulin resistance and inflammatory markers in
25
26 patients with the metabolic syndrome. *Nutr Metab Cardiovasc Dis*
27
28 2011;**21(2)**:126-35. doi: 10.1016/j.numecd.2009.08.005
- 29
30 15. Hernández-Alonso P, Salas-Salvadó J, Baldrich-Mora M, *et al.* Beneficial effect
31
32 of pistachio consumption on glucose metabolism, insulin resistance,
33
34 inflammation, and related metabolic risk markers: a randomized clinical trial.
35
36 *Diabetes Care* 2014;**37(11)**:3098-105. doi: 10.2337/dc14-1431
- 37
38 16. Grosso G, Yang J, Marventano S, *et al.* Nut consumption on all-cause,
39
40 cardiovascular, and cancer mortality risk: a systematic review and
41
42 meta-analysis of epidemiologic studies. *Am J Clin Nutr* 2015;**101(4)**:783-93.
43
44 doi: 10.3945/ajcn.114.099515
- 45
46 17. Dreher M, Maher C, Kearney P. The traditional and emerging role of nuts in
47
48 healthful diets. *Nutr Rev* 1996;**54(8)**:241-45.
- 49
50 18. Katsagoni C, Georgoulis M, Papatheodoridis G, *et al.* Associations Between
51
52 Lifestyle Characteristics and the Presence of Nonalcoholic Fatty Liver
53
54 Disease: A Case-Control Study. *Metab Syndr Relat Disord* 2017;**15(2)**:72-79.
55
56 doi: 10.1089/met.2016.0105
- 57
58 19. Ke L, Toshiro T, Fengyan S, *et al.* Relative validity of a semi-quantitative food
59
60 frequency questionnaire versus 3 day weighed diet records in middle-aged
inhabitants in Chaoshan area, China. *Asian Pacific journal of cancer*

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- prevention* : *APJCP* 2005;**6(3)**:376-81.
20. Mansournia MA, Jewell NP, Greenland S. Case-control matching: effects, misconceptions, and recommendations. *European journal of epidemiology* 2018;**33(1)**:5-14. doi: 10.1007/s10654-017-0325-0
21. Fadelu T, Zhang S, Niedzwiecki D, *et al.* Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2018;**36(11)**:1112-20. doi: 10.1200/JCO.2017.75.5413
22. Fuchs MA, Sato K, Niedzwiecki D, *et al.* Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance). *PloS one* 2014;**9(6)**:e99816. doi: 10.1371/journal.pone.0099816
23. Meyerhardt JA, Sato K, Niedzwiecki D, *et al.* Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. *Journal of the National Cancer Institute* 2012;**104(22)**:1702-11. doi: 10.1093/jnci/djs399
24. Han JM, Jo AN, Lee SM, *et al.* Associations between intakes of individual nutrients or whole food groups and non-alcoholic fatty liver disease among Korean adults. *Journal of Gastroenterology and Hepatology* 2014;**29(6)**:1265-72. doi: 10.1111/jgh.12520
25. Edens M, Kuipers F, Stolk R. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. *Obes Rev* 2009;**10(4)**:412-19. doi: 10.1111/j.1467-789X.2009.00594.x
26. Lonardo A, Ballestri S, Guaraldi G, *et al.* Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. *World J Gastroenterol* 2016;**22(44)**:9674-93. doi: 10.3748/wjg.v22.i44.9674
27. Gastaldelli A. Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD? *Clin Sci* 2017;**131(22)**:2701-04. doi: 10.1042/CS20170987

- 1
2
3
4 28. Panchal SK, Ward L, Brown L. Ellagic acid attenuates high-carbohydrate, high-fat
5 diet-induced metabolic syndrome in rats. *Eur J Nutr* 2013;**52(2)**:559-68. doi:
6 10.1007/s00394-012-0358-9
7
8
9
10 29. Polce S, Burke C, França L, *et al.* Ellagic Acid Alleviates Hepatic Oxidative
11 Stress and Insulin Resistance in Diabetic Female Rats. *Nutrients*
12 2018;**10(5)**:1-15. doi: 10.3390/nu10050531
13
14
15 30. Sato K, Gosho M, Yamamoto T, *et al.* Vitamin E has a beneficial effect on
16 nonalcoholic fatty liver disease: a meta-analysis of randomized controlled
17 trials. *Nutrition* 2015;**31(7-8)**:923-30. doi: 10.1016/j.nut.2014.11.018
18
19
20
21 31. Himoto T, Yoneyama H, Kurokohchi K, *et al.* Selenium deficiency is associated
22 with insulin resistance in patients with hepatitis C virus-related chronic liver
23 disease. *Nutr Res* 2011;**31(11)**:829-35. doi: 10.1016/j.nutres.2011.09.021
24
25
26
27 32. Sid V, Siow Y, O K. Role of folate in nonalcoholic fatty liver disease. *Can J*
28 *Physiol Pharmacol* 2017;**95(10)**:1141-48. doi: 10.1139/cjpp-2016-0681
29
30
31 33. Hajighasem A, Farzanegi P, Mazaheri Z. Effects of combined therapy with
32 resveratrol, continuous and interval exercises on apoptosis, oxidative stress,
33 and inflammatory biomarkers in the liver of old rats with non-alcoholic fatty
34 liver disease. *Arch Physiol Biochem* 2018:1-8. doi:
35 0.1080/13813455.2018.1441872
36
37
38
39
40
41 34. Jeznach-Steinhagen A, Ostrowska J, Czerwonogrodzka-Senczyna A, *et al.*
42 [Dietary recommendation for non-alcoholic fatty liver disease]. *Pol Merkur*
43 *Lekarski* 2017;**43(258)**:281-86.
44
45
46
47 35. Musa-Veloso K, Venditti C, Lee H, *et al.* Systematic review and meta-analysis of
48 controlled intervention studies on the effectiveness of long-chain omega-3
49 fatty acids in patients with nonalcoholic fatty liver disease. *Nutr Rev*
50 2018;**0(0)**:1-22. doi: 10.1093/nutrit/nuy022
51
52
53
54 36. Mohammadifard N, Yazdekhosti N, Stangl G, *et al.* Inverse association between
55 the frequency of nut consumption and obesity among Iranian population:
56 Isfahan Healthy Heart Program. *Eur J Nutr* 2015;**54(6)**:925-31. doi:
57 10.1007/s00394-014-0769-x
58
59
60

- 1
2
3
4 37. Hernández-Alonso P, Camacho-Barcia L, Bulló M, *et al.* Nuts and Dried Fruits:
5 An Update of Their Beneficial Effects on Type 2 Diabetes. *Nutrients*
6 2017;**9(7)**:673. doi: 10.3390/nu9070673
7
8
9 38. Hosseinpour-Niazi S, Hosseini S, Mirmiran P, *et al.* Prospective Study of Nut
10 Consumption and Incidence of Metabolic Syndrome: Tehran Lipid and
11 Glucose Study. *Nutrients* 2017;**9(10)**:1056. doi: 10.3390/nu9101056
12
13
14 39. Wu L, Wang Z, Zhu J, *et al.* Nut consumption and risk of cancer and type 2
15 diabetes: a systematic review and meta-analysis. *Nutr Rev* 2015;**73(7)**:409-25.
16 doi: 10.1093/nutrit/nuv006
17
18
19 40. Schlörmann W, Birringer M, Böhm V, *et al.* Influence of roasting conditions on
20 health-related compounds in different nuts. *Food Chem* 2015;**180**:77-85. doi:
21 10.1016/j.foodchem.2015.02.017
22
23
24 41. Hosseini Bai S, Darby I, Nevenimo T, *et al.* Effects of roasting on kernel peroxide
25 value, free fatty acid, fatty acid composition and crude protein content. *PLoS*
26 *ONE* 2017;**12(9)**:e0184279. doi: 10.1371/journal.pone.0184279
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

Figure 1. Odds ratios (OR) and 95% CIs for NAFLD across the strata of various factors.

The forest plot represents the ORs of the comparison of the lowest nut-intake category versus the highest nut-intake category, adjusting for age, income, smoking status, educational level, tea-drinking status, occupational status, marital status, BMI, physical activity, history of diabetes, hypertension and hyperlipidemia, total energy intake, and MUFA and PUFA intake. P -values are two-tailed; P_{inter} indicates P for the interaction between strata and nut intake; P_{trend} indicates P for the trend across levels of nut intake.




Figure 1. Odds ratios (OR) and 95% CIs for NAFLD across the strata of various factors. The forest plot represents the ORs of the comparison of the lowest nut-intake category versus the highest nut-intake category, adjusting for age, income, smoking status, educational level, tea-drinking status, occupational status, marital status, BMI, physical activity, history of diabetes, hypertension and hyperlipidemia, total energy intake, and MUFA and PUFA intake. P-values are two-tailed; Pinter indicates P for the interaction between strata and nut intake; Ptrend indicates P for the trend across levels of nut intake.

148x159mm (96 x 96 DPI)

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *case-control studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	5
		(b) For matched studies, give matching criteria and the number of controls per case	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-6
Bias	9	Describe any efforts to address potential sources of bias	7

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6-7
		(b) Describe any methods used to examine subgroups and interactions	7
		(c) Explain how missing data were addressed	
		(d) If applicable, explain how matching of cases and controls was addressed	5
		(e) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8-9
		(b) Indicate number of participants with missing data for each variable of interest	
Outcome data	15*	Report numbers in each exposure category, or summary measures of exposure	8-9
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-10
		(b) Report category boundaries when continuous variables were categorized	10-11

		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	11
Discussion			
Key results	18	Summarise key results with reference to study objectives	12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	15
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	17

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.